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Abstract English 
Background: Early detection of psychosis has been a highly investigated field of research in the last 
20 years. However, decreasing transition rates show the need for further markers to improve 
prediction of transition of those with a potential risk of developing psychosis. 
 
Methods: In the present doctoral thesis I aimed at improving early detection of psychosis by using a 
multimodal approach. Therefore, neurocognition, (potential) biological markers namely serum and 
plasma BDNF (study 1) and, prolactin (study 2), and psychopathology (study 3) were investigated. At-
risk mental state (ARMS), first-episode psychosis (FEP), and in one study also chronic schizophrenia 
(CS) patients were recruited. Furthermore, a special focus was on potential gender differences 
because knowledge about these differences can lead to improved early detection and treatment. 
 
Results: Altered BDNF levels were found, with lowest in ARMS, intermediate in FEP, and highest in 
CS. Plasma BDNF correlated positively with executive functioning. Also, prolactin levels were found to 
be altered in antipsychotic naïve ARMS and FEP patients, with hyperprolactinemia being more 
frequent in women compared to men in both groups even after correction for the normal biological 
variation. Lastly, small gender differences were found in very first self-perceived symptoms with 
women reporting more frequently anxiety and (sub-threshold) hallucinations and men more often 
cognitive and negative symptoms. 
 
Discussion: Taken together the altered levels in the investigated biological markers are promising 
and might contribute to the improvement of early detection of psychosis. The observed small gender 
differences in psychopathology match previous results. A multimodal approach combining the 
different known predictors of psychosis is promising but more research is needed before the above 
named biological markers can be included in such a model. 
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Preface  
The present dissertation encompasses the following three original publications which have all been 
accepted or published in peer-reviewed journals: 
1. Heitz, U., Papmeyer, M., Studerus, E., Egloff, L., Ittig, S., Andreou, C., …& Riecher-Rössler, A. 
(2018). Plasma and serum brain derived neurotrophic factor (BDNF) levels and their 
association with neurocognition in at-risk mental state, first episode psychosis and chronic 
schizophrenia patients. The World Journal of Biological Psychiatry (accepted) 
 
2. Ittig, S., Studerus, E., Heitz, U., Menghini-Müller, S., Beck, K., Egloff, L., ... & Riecher-Rössler, 
A. (2017). Sex differences in prolactin levels in emerging psychosis: Indication for enhanced 
stress reactivity in women. Schizophrenia research, 189, 111-116. 
 
3. Heitz, U., Studerus, E., Menghini‐Müller, S., Papmeyer, M., Egloff, L., Ittig, S., ... & Riecher‐
Rössler, A. (2017). Gender differences in first self‐perceived signs and symptoms in patients 
with an at‐risk mental state and first‐episode psychosis. Early intervention in psychiatry.  
M.Sc. Ulrike Heitz  A multi-perspective approach to early detection of psychosis  
- 9 - 
 
Introduction 
Over the last 20 years research has focused on the early detection of psychosis. The aim of these 
efforts is to detect people with a so called at-risk mental state (ARMS) for psychosis before they 
potentially develop the full-blown illness to decrease the time of untreated psychosis (DUP), and 
subsequently improve the treatment outcome, or ideally even to prevent the onset of psychosis 
(Fusar-Poli et al., 2012).  
In the following I will give a brief overview of the following topics. First, I will elucidate the 
importance and current knowledge in the field of research of early detection of psychosis. Second, 
the results regarding psychopathology in ARMS as compared to first-episode psychosis (FEP) patients 
will be described. Third, the current knowledge of neuropsychological deficits in FEP and ARMS will 
be reviewed. Fourth, the present knowledge regarding potential biomarkers, especially peripheral 
brain-derived neurotrophic factor (BDNF) and prolactin will be reviewed. Fifth, the psychopathology 
of FEP and ARMS will be reviewed. Sixth, gender specific knowledge in FEP and ARMS will be 
summarized.  And lastly, the hypothesis of the present doctoral thesis will be given. 
 
Early detection of psychosis 
Psychosis is still considered as one of the most severe mental illnesses. It has an important impact on 
the patients, their families but also regarding health care costs. Even though, the live time prevalence 
is only about 1 percent according to a recent review the costs are estimated to range from 0.02% to 
1.65% of the gross domestic product with 80% of the included studies coming from high-income 
countries (Chong et al., 2014).  
A fast onset of an adequate treatment of psychosis is considered to be of great importance for the 
later prognosis of the illness. It has been found that a delayed treatment can have severe negative 
consequences on several domains which will be briefly named in the following. The prognosis is 
poorer and the remission of the symptom is later and/ or incomplete. Furthermore, the compliance 
of the concerned individuals has been found to be poorer with a delayed treatment which in turn 
again impacts the prognosis. Also, the cognitive performances were found to deteriorate further with 
a delayed treatment onset. Moreover, the psychological and social development are stronger 
impaired and the quality of live was found to be lower in patients with a later treatment. Considering 
all these points it is understandable that the costs for the health care system are increased and that 
the burden for the patients and the families are heavier (Olesen et al., 2012). 
As a result of these negative consequences of a delayed treatment of psychosis researches have 
focused on investigating the prodromal phase of this illness.  
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Definition of an at-risk mental state 
It is now known, that in most cases the onset of a full-blown psychosis is preceded by a so called 
prodromal phase as shown in Figure 1. The following risk criteria are commonly used to detect ARMS 
patients (Fusar-Poli et al., 2012): 
• Basic symptoms (BS): There exist different definitions of basic symptoms. Basic 
symptoms are subtle, subclinical disturbances in stress tolerance, drive, affect, thinking, 
speech, (body) perception, motor action, and central-vegetative functions that are self-
experienced with full insight into their abnormal nature(Schultze-Lutter & Theodoridou, 
2017). 
• Genetic Risk and Deterioration syndrome (GRD): Since it is known that there is a high 
genetic component in the development of psychosis, many research groups also include 
patients with first degree relatives in their at-risk group. Most study groups combine this 
category with a drop in functioning or other symptoms are present and only include 
patients if both are present. 
• Attenuated psychotic symptoms (APS): These describe sub-threshold psychotic 
symptoms which differ in terms of intensity from full-blown psychotic symptoms e.g. 
alterations in perception such as hearing noises but knowing that these are not real as 
compared to acoustic hallucinations of voices with the persuasion that these are real. 
These symptoms must be present at least several times per week persisting for more 
than one week. 
• Brief Limited Intermittent Psychotic Symptoms (BLIPS): Defined as clearly psychotic 
symptoms with an intensity as seen in a full-blown psychotic episode but lasting no 
longer than 7 days and remitting spontaneously without antipsychotic medication. 
M.Sc. Ulrike Heitz  A multi-perspective approach to early detection of psychosis  
- 11 - 
 
 
Figure 1: Model of psychosis onset from the clinical high-risk state. The higher the line on the y-axis, the higher the symptom 
severity (from Fusar-Poli et al., 2013) 
Depending on the study protocol the above described prodromal states are used to assess if a 
patient is at-risk of developing psychosis. Accordingly, different instruments have been developed to 
assess the risk status. The most common are listed in Table 1. 
Name Author (Year) Risk categories 
BSABS (Bonn Scale for the 
Assessment of Basic 
Symptoms)  
Gross et al. (1987) BS 
BSIP (Basel Screening 
Instrument for Psychosis) 
Riecher-Rössler et al. (2008) APS 
BLIPS 
GRD 
“Unspecific risk category” 
CAARMS (Comprehensive 
Assessment of At-risk Mental 
States) 
Yung et al. (2005) APS 
BLIPS 
GRD 
SPI-A (Schizophrenia 
Proneness Instrument, Adult 
version) 
Miller et al. (1999) BS 
SIPS (Structured Interview for 
Prodromal Symptoms) 
McGlashan et al. (2001) APS 
BLIPS 
GRD 
Table 1: Overview of commonly used interviews assessing a potential at-risk mental state. 
Patients with a risk status are hence defined slightly differently depending on the instrument used 
and the research group. Accordingly, also the name given to patients with an elevated risk for 
developing psychosis vary depending on these factors. The following terms are the most commonly 
used ones: 
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• ARMS: At-risk mental state 
• CHR: clinical-high risk 
• UHR: ultra-high risk 
• PRS: psychosis risk syndrome 
In the present thesis the term ARMS will be used. Independent of the diagnostic criteria, a significant 
clinical distress can be observed in patients with an ARMS. Therefore, those who fulfil these criteria 
are referred to as being “patients” instead of individuals in this thesis to account for the clinical 
implications of the risk status.  
It should be noted that recently the “attenuated psychosis syndrome” (APS) has been incorporated in 
the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (American Psychiatric 
Association, 2013) in Section III under “conditions for further study” showing the growing recognition 
and importance of subthreshold psychotic experiences and the (potential) prodromal phase of 
psychotic disorders. 
 
Transition to psychosis 
The transition to psychosis is commonly defined according to the criteria developed by Yung et al., 
(1998): At least one positive psychotic symptom occurring at least several times per week for more 
than one week. The following symptoms are therefore considered according to their definition in the 
Brief Psychiatric Rating Scale (BPRS): Hallucinations (≥ 4); Unusual thought content (≥ 5); 
Suspiciousness (≥ 5); Conceptual disorganisation (≥ 5). 
At the beginning of this field of research transition rates were found to be as high as 50% within the 
first year of follow-up (Miller et al., 2002). However, in recent years transition rates have been found 
to decrease as summarized in a meta-analysis finding transition rates of 18% after 6 months of 
follow-up, 22% after 1 year, 29% after 2 years, and 36% after 3 years (Fusar-Poli et al., 2012). A 
recent study with a cohort of 202 ultra-high risk individuals who were followed up for 12 months 
found a transition rate of only 15.8% (Polari et al., 2018). Several potential reasons for this drop in 
transition rates have been suggested such as earlier and more accurate interventions for those at risk 
(Simon, Umbricht, Lang, & Borgwardt, 2014; Alison R. Yung et al., 2007).  This increase of false 
positives however shows the need for further markers for those truly at risk to improve the 
prediction of transition.  
In an attempt to improve the prediction of transition to psychosis the North American Prodrome 
Longitudinal Study (NAPLS) developed an Individualized Risk Calculator (Cannon et al., 2016) which 
was also validated by another group (Carrión et al., 2016) using a multimodal approach including 
different potential predictors of transition to psychosis. This approach also offers the benefit for the 
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concerned patients to have a more accurate estimation of their individual risk of transition which in 
turn might lead to more individualized treatment options such as pharmacological interventions for 
those with a high risk of transition. 
 
The FePsy Study 
The studies of the present doctoral thesis were part of the FePsy (Früherkennung für Psychosen; 
English: early detection of psychosis) project which is conducted at the Universitäre Psychiatrische 
Kliniken (UPK; English: University of Basel Psychiatric Hospital) Switzerland.  
FePsy is an open, prospective clinical study aiming at facilitating and improving the early assessment 
of beginning psychoses respectively of the risk for psychosis and contributing to the knowledge 
about the potential prodromal stage of this disorder and improving the prediction of transition to 
psychosis. 
Patients are thoroughly examined at study entry and ARMS patients are followed up for 5 years. 
Follow-ups take place monthly during the first year, every three months during year two and three, 
and annually in the last two years of the study. See Figure 2 for a flowchart of the procedure.  
 
Figure 2: Design of the FEPSY Study. 
The following clinical interviews are part of the FePsy study (in order of conduct): BSIP (Riecher-
Rössler et al., 2008), Structured Clinical Interview for DSM (SCID; First, Gibbon, Spitzer, & Benjamin, 
1997) and BIP (A. Riecher-Rössler et al., 2015). BPRS (Lukoff, Nuechterlein, & Ventura, 1986; Ventura 
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et al., 1993) and Scale for the Assessment of Negative Symptoms (SANS; Andreasen, 1989) are used 
as observer-rating instruments. The participants are also asked to complete the following self-rating 
questionnaires: Frankfurt Complaint Questionnaire (FCQ) and paranoid scale (PS). In addition, a 
neuropsychological assessment is carried out testing multiple cognitive domains (see below). Finally, 
MRI, EEG and blood tests are also part of the initial assessment.  
At the follow-up assessments only the clinical interviews are repeated with the BPRS being used for 
the monthly and three-monthly assessments and BIP, SANS and BPRS at the annual assessments.  
In the FePsy study a case-manager (CM) approach is used. Each patient is taken care of by one CM 
throughout the entire screening and follow-up period, e.g. all different assessments such as EEG, MRI 
and clinical interviews are organized by the CM and the interviews are also carried out by the 
responsible CM. Case-managers are either psychologists or psychiatrists who get an extensive 
training prior to their first assessments. Moreover, all CM participate in monthly psychopathology 
trainings which include all used scales and interviews. The trainings are conducted by experienced 
clinical psychologist or the head psychiatrist. 
Further details regarding the FePsy study procedure can be found in previous publications (Riecher-
Rössler et al., 2007, 2009). 
 
Neurocognition 
Neurocognition in FEP 
Neurocognitive deficits have been a core symptom of psychotic disorders since their first description 
by Kraepelin who initially called his observed syndrome “dementia praecox” as severe cognitive 
deficits seemed to be the core of the disorder. Nowadays it is known that neurocognitive deficits are 
only one of the main symptoms of psychotic disorders, but they are still considered as one of its core 
features. 
Cognitive deficits can be observed already in patients with an ARMS, have repeatedly been found in 
FEP patients and continue to exist over the course of the disorder. However, recent meta-analysis did 
show that these deficits do not deteriorate over time but seem to be rather stable after illness onset.  
Cognitive deficits have been observed in almost all cognitive domains including working memory, 
verbal memory, executive  function, attention, speed of information processing and visuo-spatial 
abilities (Bora & Murray, 2014; Fusar-Poli, Deste, et al., 2012; Hauser et al., 2017). 
 
Neurocognition in ARMS 
Also, in ARMS patients, significant cognitive deficits have been found across cognitive domains. 
Hence cognitive performances have also been used to improve the prediction of a transition to 
psychosis (Studerus, 2016). 
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A recent meta-analysis by Hauser et al. (2017) revealed the following: Compared to HCs, people with 
CHR performed significantly worse in 7 of 9 domains (attention/vigilance Hedges g effect size [95% 
confidence limit] = -0.17 [-0.30, -0.04]; verbal learning, speed of processing g=0.42 [-0.64, -0.20]; 
social cognition g=-0.43 [-0.68, -0.18]). Compared to FEP subjects, people with CHR performed 
significantly better in 5 of 6 domains (speed of processing g=0.29 [0.03, 0.56]; attention/vigilance, 
verbal learning g=0.39 [0.17, 0.62]; working memory g=-0.40 [0.18, 0.64]). Those with a later 
transition to psychosis performed significantly worse in 6 of 8 domains (attention/vigilance g=-0.24 [-
0.44, -0.03]; verbal learning  g=-0.49 [-0.76, -0.22]; visual learning g=-0.54 [-0.80, -0.27]).  
Other reviews and meta-analyses found similar results with cognitive deficits being already present in 
ARMS and being more pronounced in those with later transition as compared to those without 
transition (Bora & Murray, 2014). 
Overall cognitive deficits seem to exist already in the prodromal phase of psychosis and might 
improve the prediction of transition in those individuals at risk.  
 
Biological markers 
Overview of biological markers 
In an attempt to further improve the prediction rate of ARMS patients to full-blown psychosis 
numerous potential biomarkers have been investigated. In a recent review of investigated 
biomarkers (Anita Riecher-Rössler & Studerus, 2017)  the authors found the following biological 
approaches in early detection of psychosis: MRI (structural and functional), EEG, ERP, cognition, 
visual saccades, binocular depth inversion, olfactory deficits, metabolic/ proteomic profiles, cortisol 
and genes.  
Considering the number of potential biomarkers in the field of early detection of psychosis the focus 
will only be on prolactin and BDNF in the following. 
Prolactin was chosen since hyperprolactinemia has been found in antipsychotic-naïve ARMS and FEP 
patients and as dopamine is the main prolactin inhibiting factor and is thought to be involved in the 
aetiology psychotic disorders. Moreover, hyperprolactinemia it is a known side effect of 
antipsychotics. Additionally, prolactin is also synthesized in response to stress. Based on all these 
findings the inclusion of this potential biomarker was made (Ittig et al., 2017). 
BDNF was of special interest due to its role in cognitive processes (Carlino, De Vanna, & Tongiorgi, 
2013) which are a core deficit in psychotic disorders and are also already present in the prodromal 
phase as described above. 
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Prolactin 
Prolactin is a polypeptide hormone which is secreted by lactotroph cells of the anterior pituitary 
gland. It is involved in numerous biological functions, such as reproduction related processes 
including pregnancy and lactation, but also in growth and development. Prolactin secretion can be 
influenced by several factors namely gender, smoking, childbirth or psychopharmacological 
medication. Furthermore, it is also released in response to psychosocial stress (Fitzgerald & Dinan, 
2008; Lennartsson & Jonsdottir, 2011).   
Prolactin secretion is mainly regulated by dopamine which is considered to be the main prolactin 
inhibiting factor (PIF) (Fitzgerald & Dinan, 2008).   
Hyperprolactinemia can lead to numerous adverse effects such as amenorrhea and galactorrhea, an 
acceleration of osteoporosis in women, and a lack of libido and erectile dysfunction in men, and may 
increase the risk of breast cancer in women (Rajkumar, 2014). 
Prolactin in FEP  
Two observations lead to an increasing interest in prolactin in FEP patients. First, antipsychotic 
medication act on the dopaminergic system, specifically the D2 receptor (Bennett, 1998) and it was 
found that dopamine neurotransmission is involved in the pathophysiology of psychosis (Howes et 
al., 2009). Furthermore, hyperprolactinemia was often observed as an adverse effect of antipsychotic 
treatments in schizophrenic patients (Peuskens, Pani, Detraux, & De Hert, 2014). Second, increasing 
evidence points towards the role of psychosocial stress in the development of psychotic symptoms 
(Aiello, Horowitz, Hepgul, Pariante, & Mondelli, 2012; van Winkel, Stefanis, & Myin-Germeys, 2008). 
As described above psychosocial stress is also known to influence the secretion of prolactin. It was 
therefore considered to be of interest to investigate the potential influence of prolactin on the 
development of psychotic disorders especially in interaction with psychosocial stress.  
Studies investigating prolactin in participants suffering from psychotic disorders found correlations 
between the stress hormone prolactin and psychopathological symptoms (Rajkumar, 2014). 
Interestingly, it was also found that hyperprolactinemia does not only exist in psychotic patients 
receiving antipsychotics but also already in antipsychotic-naïve FEP patients. For example the 
European First Episode Schizophrenia Trial (EUFEST) found elevated prolactin levels in 40.5% of 
antipsychotic-naïve FEP patients (Riecher-Rössler et al., 2013).  
These authors suggested the following explanation for these observations: as psychosocial stress is 
involved in the development of psychotic symptoms and is equally known to lead to prolactin 
synthesis and release it might hence possible that stress induces hyperprolactinemia and the release 
of dopamine is subsequently increased to down-regulate prolactin, leading to an increase of 
psychotic symptoms (Riecher-Rössler et al., 2013).  
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Prolactin in ARMS 
Regarding prolactin levels in ARMS patients only few studies exist so far. Aston et al. (2010) found 
hyperprolactinemia in 23.8% of ARMS patients who were all antipsychotic-naïve. Labdad et al. (2015) 
also investigated a potential correlation of prolactin levels with a later transition to psychosis in 
ARMS patients and found that those with a later transition had higher prolactin levels than those 
without later transition. However, in a Cox Regression adjusted for sex, cannabis use and 
antidepressant treatment prolactin was not associated with the time to psychosis transition. 
Furthermore Perkins et al. (2015), used a machine learning algorithm to improve prediction of 
transition to psychosis. In their model prolactin was not selected as a potential predictor of transition 
in a sample of 72 ARMS patients. 
 
BDNF  
BDNF is the most common neurotrophin in the human brain. It is known to be involved in the 
synthesis, differentiation, maintenance, and survival of neurons, both in the central and in the 
peripheral nervous system (Kuipers & Bramham, 2006). It has repeatedly been shown to have an 
important role in cognitive processes especially learning and memory, as supported by animal 
(Bekinschtein et al., 2008; Yamada & Nabeshima, 2003) and human studies (Carlino et al., 2013).  
In line with these findings BDNF is found to be highly expressed in cortical areas involved in these 
cognitive processes such as hippocampal and prefrontal areas (Bekinschtein et al., 2008; Conner, 
Lauterborn, Yan, Gall, & Varon, 1997). 
BDNF can also be detected in the peripheral nervous system, where it can be assessed in blood 
serum and plasma. Although the exact source of the peripheral BDNF is not yet completely 
understood, it is known that BDNF can cross the blood-brain barrier, as shown in animal studies (Pan, 
Banks, Fasold, Bluth, & Kastin, 1998). Additionally, cortical and peripheral BDNF levels have been 
found to correlate positively in various animal studies (Karege, Schwald, & Cisse, 2002; Klein et al., 
2011). 
BDNF in FEP  
Due to the well-known cognitive deficits in patients with psychotic disorders and the role of BDNF in 
cognitive impairments this patient group has become a focus of interest and cortical and peripheral 
BDNF levels were found to be altered in patients with schizophrenia. Post-mortem studies in these 
patients allowed to localise altered central BDNF levels in memory related areas such as the 
hippocampus (Durany et al., 2001; Weickert et al., 2003). A study investigating serum BDNF levels 
and those assessed in the cerebrospinal fluid also found a positive correlation of these two measures 
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(Pillai et al., 2010). Based on the so far described knowledge about the correlation of cortical and 
peripheral BDNF levels in general and in this patient group the peripheral measure of serum and 
plasma BDNF are commonly used in this field of research.  Reviews and meta-analyses of peripheral 
BDNF levels in patients with schizophrenia point towards decreased levels in FEP patients which 
further decrease in chronic, and accordingly older, psychosis patients (Buckley, Pillai, & Howell, 2011; 
Fernandes et al., 2014; Green, Matheson, Shepherd, Weickert, & Carr, 2011; Martinotti et al., 2012; 
Toll & Mane, 2015). 
The potential association of peripheral BDNF levels and cognitive performances in patients with 
schizophrenia has also been investigated in several studies. While most of these studies point 
towards a positive association of certain cognitive functions with peripheral BDNF levels (Asevedo et 
al., 2013; Carlino et al., 2011; Hori et al., 2017; Niitsu et al., 2011; Ruiz de Azua et al., 2013; Zhang, 
Chen da, et al., 2012; Zhang, Liang, et al., 2012) others found mixed results, i.e., positive or negative 
correlations of peripheral BDNF with cognition depending on the assessed cognitive domain (Niitsu 
et al., 2014; Xiao et al., 2017) or no association between these two parameters (Buckley, Pillai, Evans, 
Stirewalt, & Mahadik, 2007; Fisher, Mellon, Wolkowitz, & Vinogradov, 2016; Goto et al., 2009; Man 
et al., 2018; Theleritis et al., 2014; Vinogradov et al., 2009). The authors of a  meta-analysis  
concluded  that  there  is  a  small  but  significant positive  association  of  peripheral  BDNF  with  
reasoning  and  problem-solving,  and  with overall cognitive capacity in patients with schizophrenia 
(Ahmed, Mantini, Fridberg, & Buckley, 2015).   
BDNF in ARMS 
Despite the strong interest in the prodromal phase of psychosis and the above described observed 
onset of cognitive deficits prior to transition to frank psychosis, no study investigated peripheral 
BDNF levels in an ARMS sample at the time of submission of our article investigating this aspect. 
However, recently the first findings regarding peripheral BDNF levels in ARMS patients was published 
from the Longitudinal Youth at Risk Study (Yee, Lee, & Lee, 2018). According to the authors, ARMS 
patients had significantly higher baseline levels of serum BDNF compared with a healthy control 
group. However, baseline levels of serum BDNF did not predict the development of psychosis or 
remission from the ARMS status.  
 
Gender specific aspects of psychosis 
Gender differences in schizophrenic psychoses have been discussed since the beginning of research 
in this field. Already Kraepelin described an earlier onset in men with poorer premorbid 
development, more affective flattening and social anhedonia as compared to female patients 
(Lewine, 1988). 
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The aim of the research investigating potential gender differences in patients suffering from 
psychotic disorders is to better understand the aetiology of the disorder, and to further improve the 
treatment with potentially gender specific interventions. 
In the field of early detection, the knowledge about potential gender differences might contribute to 
an improvement of the detection of individuals at-risk and to further improve the prediction of 
transition. 
Gender specific aspects in FEP  
An earlier age of onset in men is one of the most replicated findings regarding gender differences in 
schizophrenia (see Figure 1Figure 3), while women have a second peak of illness onset around 
menopause (Cascio, Cella, Preti, Meneghelli, & Cocchi, 2012; Eranti, MacCabe, Bundy, & Murray, 
2013; Häfner et al., 1991, 1993, 1998). It has been suggested that the higher oestrogen levels in 
women prior to menopause have a protective effect leading to the later age of onset (Häfner et al., 
1991, 1993; Anita Riecher-Rössler, 2017). 
 
 
Figure 3: Differences between men and women: *p≤0.05; p≤0.01. (First episode sample of broad definition schizophrenia, 
n=232.), from Häfner et al (1998). 
Additionally, recent reviews indicate a slightly increased incidence of schizophrenic psychoses in men 
compared to women (Aleman, Kahn, & Selten, 2003; McGrath, 2006; van der Werf et al., 2014). 
Moreover, men have been found to abuse substances more frequently and to have less illness 
insight, worse treatment adherence, and poorer functional and social outcome (Abel, Drake, & 
Goldstein, 2010; Ochoa, Usall, Cobo, Labad, & Kulkarni, 2012). Regarding symptomatology research 
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points toward more negative symptoms and lower levels of (social) functioning in men and more 
affective and positive psychotic symptoms in women (Cotton et al., 2009; Thorup et al., 2014; 
Waford et al., 2015). However, these findings are not consistent with some groups finding no or only 
small gender differences regarding symptomatology (Barajas, Ochoa, Obiols, & Lalucat-Jo, 2015; 
Bertani et al., 2012).  
Potential gender differences have also been investigated in biological markers of psychosis. For 
example the meta-regression of gender conducted by Nordholm (2013) suggests that differences in 
male/female ratio between patients and controls do have a major impact on pituitary gland volume, 
with a bigger pituitary volume in females. Also regarding hormonal functioning gender differences in 
patients with psychosis have been found (Canuso & Pandina, 2007; Anita Riecher-Rössler, 2017).  
Gender specific aspects in ARMS 
In order to get a better understanding of the origin of psychosis and to further improve early 
detection and prediction of transition potential gender differences have also been investigated in 
ARMS patients. 
Poorer performances in men as compared to women in social and role functioning was found in 
ARMS patients, similar to the pattern observed in FEP patients (Barajas et al., 2015; Willhite et al., 
2008).  
Also, regarding symptomatology similar patterns were found in ARMS patients as compared to FEP 
patients, with men showing more severe negative and cognitive symptoms, while more positive sub-
threshold psychotic symptoms and affective symptoms were found in female ARMS patients (Barajas 
et al., 2015; Corcoran et al., 2011; Holtzman, Shapiro, Trotman, & Walker, 2012; Willhite et al., 2008). 
However, other studies could not confirm these gender differences in symptomatology (Gonzalez-
Rodriguez et al., 2014; Johnstone, Ebmeier, Miller, Owens, & Lawrie, 2005; Lemos-Giraldez et al., 
2009; Rössler, Hengartner, Ajdacic-Gross, Haker, & Angst, 2012; Willhite et al., 2008; Ziermans, 
Schothorst, Sprong, & van Engeland, 2011).  
Cocchi et al (2014) suggested that this discrepancy between findings in FEP and ARMS stems from 
the limitation that only a minority of ARMS patients develop full-blown psychosis which might 
explain why sex differences are less evident in ARMS samples.  
The potential impact of gender specific knowledge on prediction of transition was investigated by 
Walder et al. (2013) who found that poorer baseline social functioning and baseline positive 
prodromal symptoms predicted significantly greater risk of conversion among males only.  
Regarding potential gender differences in biological markers of ARMS patients no sound data are yet 
available as the research on these markers in this patient group is still ongoing. 
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Aim & Hypotheses 
The aim of the present doctoral thesis was to contribute to the scientific knowledge about different 
characteristics of ARMS patients with the intention to advance the detection of individuals at risk and 
to improve the prediction of transition to psychosis in these individuals.  
More specifically peripheral BDNF and prolactin levels were investigated to get a better 
understanding of the biological underpinnings of an emerging psychotic disorder, and in the case of 
BDNF their potential association with cognitive functioning in ARMS and FEP patients. Furthermore, 
potential gender differences in first self-perceived signs and symptoms were investigated to assess 
whether they might contribute to an improved early detection. 
 
Hypotheses regarding peripheral BDNF levels 
1. Both plasma and serum BDNF are highest in ARMS, intermediate in FEP, and lowest in CS 
2. Higher BDNF levels are associated with better cognitive performance in all patient groups 
 
Hypotheses regarding prolactin levels 
1. Increased frequencies of hyperprolactinemia in ARMS and FEP patients 
2. Higher prolactin levels in FEP as compared to ARMS patients 
3. More elevated prolactin levels in men than in women after correction for normal gender 
variations 
4. A positive association of prolactin with psychopathological symptoms  
5. Higher baseline prolactin levels being predictive of transition to psychosis in ARMS patients 
 
Hypothesis regarding potential gender differences in the symptomatology 
1. Overall only small gender differences would be observable in the first self-perceived 
symptoms of ARMS and FEP patients 
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Discussion 
Discussion of BDNF results 
The observed pattern of higher peripheral BDNF levels in CS, intermediate in FEP and lowest in ARMS 
patients contradicts our hypothesis and previous research regarding the CS and FEP group (Green et 
al., 2011; Martinotti et al., 2012).  
Regarding BDNF levels in ARMS only one recently published study exists so far. In this publication 
ARMS were found to have higher serum BDNF levels when compared to a healthy control group (Yee 
et al., 2018). Unfortunately, in our study we did not assess an HC group.  
Furthermore, BDNF levels vary substantially between studies so that a direct comparison of the 
observed levels is also not suitable (Green et al., 2011). There are numerous potentially influencing 
factors regarding peripheral BDNF levels such as age (Xiu et al., 2009), gender (Begliuomini et al., 
2007), medication (Rizos et al., 2010), nicotine (Bhang, Choi, & Ahn, 2010), stress (Brunelli et al., 
2012), body weight (Pillai et al., 2012), season and sunlight (Molendijk et al., 2012). The so far 
existing studies vary regarding those influencing factors taken into account. It might hence be 
possible that those methodological differences lead to the observed differences in BDNF levels. 
Simply creating a mean of the so far measured BDNF levels does hence not seem to be appropriate 
considering the amount of potentially influencing factors and the considerable differences in BDNF 
levels. Taken together, no firm conclusion about BDNF levels in ARMS patients can be drawn yet. It 
seems however, that in both studies an unexpected pattern was observed, which deserves further 
investigation. 
Due to the small sample size we were unable to differentiate further between those ARMS with and 
without later transition to psychosis. A prediction regarding the risk of transition based on BDNF 
levels is hence not possible based on our data. However, in the one existing study also investigating 
serum BDNF levels in an ARMS sample, the authors found no predictive value of baseline serum 
BDNF levels. Similarly, BDNF levels also did not predict remission from the ARMS status (Yee et al., 
2018).  
Based on these surprising results it is not yet possible to draw any firm conclusions regarding 
peripheral BDNF levels in patients with schizophrenia over the course of the illness, and especially in 
the (potential) prodromal phase. Nevertheless, the surprisingly low BDNF levels in ARMS patients 
might point towards pathological processes preceding the transition to psychosis. Regarding our data 
it might also be speculated that BDNF levels normalize during the  course  of  the  illness  and  
possibly  due  to  the  (pharmacological)  treatment  of the patients, while cognitive deficits persist, 
which has been shown in previous meta-analyses of longitudinal studies (Bora & Murray, 2014; Irani, 
Kalkstein, Moberg, & Moberg, 2011). 
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Plasma BDNF levels were significantly and positively associated with Tower of Hanoi (ToH) 
performance, as a measure of executive function, and at a trend-level with global cognitive 
performance, which is in line with our hypothesis. Also most previous studies investigating the 
potential association between cognition and peripheral BDNF points towards a positive correlation of 
these two parameters, as supported by a recent meta-analysis (Ahmed et al., 2015) which found 
higher BDNF levels to be associated with better performances in the domain of reasoning/problem 
solving and overall performances. The author argue however that the overall association might be 
driven by the positive association of reasoning/problem solving with BDNF. The same might be true 
for our fining, i.e. that the positive association of plasma BDNF with ToH performances lead to the 
trend-wise association of BDNF and global cognitive performances.  
To improve our knowledge about peripheral BDNF levels in (emerging) psychosis the following 
considerations should be taken into account in future study designs. Bigger sample sizes are needed, 
as well as the inclusion of a healthy as well as a clinical control group, as altered BDNF levels have 
also been found in other patient groups (Cattaneo, Cattane, Begni, Pariante, & Riva, 2016). The 
inclusion of healthy controls should also be considered due to the considerable variation of BDNF 
levels between studies, which impedes a direct comparison of BDNF levels (Green et al., 2011). In 
order to get a deeper understanding of BDNF level changes in the course of psychotic illnesses 
longitudinal designs should be favoured over our cross-sectional study design.  
Discussion of Prolactin results 
Our results of an increased percentage of hyperprolactinemia in ARMS and FEP patients matched not 
only our hypothesis but also previous studies (Aston et al., 2010; Riecher-Rössler et al., 2013).  In 
addition, we could replicate these findings in antipsychotic-naïve patients, with rigorous exclusion 
criteria and blood collection under controlled conditions.  
Prolactin levels did not differ between ARMS and FEP patients, which is accordance with Montalvo et 
al. (2014) who also compared these two groups. As there are so far only few studies comparing BDNF 
levels in those two patient samples, it might only be speculated what the mechanism behind these 
observations is. One potential explanation might be that ARMS and FEP patients have equal levels of 
stress leading to similar amounts of prolactin. However, studies investigating cortisol, a stress 
hormone, reported higher levels in FEP as compared to ARMS patients contradicting this speculation 
(Aiello et al., 2012; Holtzman et al., 2012; Walker et al., 2013). Hence, more research is needed 
before any firm conclusion can be drawn about the factors leading to increased prolactin levels in 
ARMS and FEP patients.  
Prolactin was also not found to be predictive of later transition based on our data, which is in line 
with one previous study (Perkins et al., 2015) and with the findings from Labad et al. (2015) when the 
M.Sc. Ulrike Heitz  A multi-perspective approach to early detection of psychosis  
- 24 - 
 
latter one included gender in their analysis. Taken together the few existing studies do not suggest a 
predictive value of prolactin in the prediction of transition to psychosis in ARMS patients. 
The following sex difference emerged in the sample of our study: prolactin was more increased in 
women as compared to men, even after correction for the normal biological variation. This finding 
contradicts the results of a meta-analysis by Gonzalez-Blanco et al. (2016). However, in this meta-
analysis only studies with healthy control groups were included leading to the exclusion of one 
previous study by Riecher-Rössler et al. (2013) also reporting hyperprolactinemia to be more 
frequent in antipsychotic-naïve FEP women compared to men. 
As hyperprolactinemia can have severe clinical consequences such as an acceleration of osteoporosis 
in women and a lack of libido and erectile dysfunction in men (Rajkumar, 2014; Rubio-Abadal et al., 
2016) it is of clinical importance to assess a potential alteration of prolactin levels especially in 
patients with psychotic disorders even prior to antipsychotic treatment. As these symptoms are 
often attributed to antipsychotic medication leading potentially to non-compliance regarding 
pharmacological treatment which in turn can have negative consequences regarding the prognosis of 
the illness. For all these reasons prolactin levels should be measured prior to any pharmacological 
treatment to offer the best available care. 
It should be noted that it is so far still unknown if prolactin levels are specific for emerging psychosis 
or reflect general pathological mechanisms of emerging illness. Therefore, future studies should 
ideally include clinical as well as healthy control groups. Furthermore, stress is known to influence 
prolactin levels and in the present study stress levels were not assessed. This should also be 
considered for future study designs.  
Discussion of Psychopathology results  
The observed pattern of few gender differences with women reporting more anxiety and positive  
psychotic symptoms and men reporting (trend-wise) more frequently negative and cognitive 
symptoms as being among their first self-perceived signs and symptoms at illness onset are partly in 
line with the one previous study investigating first self-perceived symptoms in FEP patients who also 
reported more worrying in women and more trouble with thinking and concentration in men (Häfner 
et al., 1995). Moreover, other previous reports investigating current symptomatology in ARMS 
(Barajas et al., 2015; Pruessner et al., 2017; Rietschel et al., 2015; Waford et al., 2015) and FEP 
(Moukas, Gourzis, Beratis, & Beratis, 2010; Thorup et al., 2007) patients also point towards more 
negative symptoms in men and more (sub-threshold) positive symptoms in women. It should 
however be noted, that other studies did not find any gender differences regarding symptomatology 
in ARMS and FEP patients (Bertani et al., 2012; Gonzalez-Rodriguez et al., 2014; Kotlicka-Antczak et 
al., 2016). 
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Taken together the existing literature, it might be speculated that small gender differences exist 
regarding symptomatology with men showing more negativeand women more anxiety or affective 
and (sub-threshold) positive symptoms. It is however likely that the effect size of this gender 
difference is rather small which might explain the heterogeneity in findings due to a lack of statistical 
power. Furthermore, Fusar-Poli et al. (2012) pointed out that gender differences might be more 
pronounced in FEP patients compared to ARMS patients due to the unspecific nature of this latter 
group.  
It should also be noted that Walder et al. (2013) suggested that the prediction of transition to 
psychosis could be improved by considering gender as it might moderate the influence of other 
important predictors, such as social functioning and positive psychotic symptoms.  
Limiting our findings, it should be noted that despite our attempt to capture the first self-perceived 
symptoms as soon as possible there were on average almost five years between the appearance of 
the first symptoms and our assessment. This might have led to some recall bias. Furthermore, illness 
insight might be impaired in patients suffering from psychotic disorders, especially during the acute 
phase (Gerretsen, Plitman, Rajji, & Graff-Guerrero, 2014) while this is less likely to be altered in the 
premorbid phase. Also men and women may differ in their symptom perception, awareness, and 
their willingness to report specific symptoms (Berger, Addis, Reilly, Syzdek, & Green, 2012). It is 
hence not possible to eliminate the possibility that the observed gender differences are at least in 
part due to reporting and recall biases.  
General discussion and further directions  
In an attempt to synthesize the results of the studies included in the present dissertation the 
following conclusions can be drawn. Peripheral BDNF levels were surprisingly low in ARMS patients 
which might point towards an important pathological process prior to the onset of full-blown 
psychosis. The positive correlation of plasma BDNF levels with executive functions might provide a 
link to the well-established cognitive deficits of psychotic disorders which are already present in 
ARMS patients (U. Heitz et al., 2018). Also, prolactin levels have been found to be altered already in 
antipsychotic-naïve ARMS and FEP patients. And hyperprolactinemia was more frequently found in 
ARMS and FEP women as compared to men even after correction for the normal biological variation. 
This might be due to a sex specific stress reaction regarding prolactin (Ittig et al., 2017). Regarding 
psychopathology only small gender differences were found with women reporting more often 
anxiety and (sub-threshold) hallucinations and men more often cognitive and negative symptoms as 
being among their first self-perceived symptoms (Ulrike Heitz et al., 2017).  
The surprisingly low BDNF levels in ARMS compared to FEP and CS patients might be a valuable 
further marker to detect individuals with an elevated risk to develop psychosis, especially when 
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combined with other biological and clinical markers such as prolactin, psychopathology or 
neuropsychology with the aim of improving the accuracy of early detection. 
It should however be noted that especially regarding the above discussed biological markers, i.e. 
prolactin and particularly BDNF, only little is known so far in ARMS samples for example regarding 
the mechanisms leading to these altered levels. So clearly more research with sound methodology 
and representative samples are needed before any firm conclusions can be drawn. We hope that the 
present studies contribute to this ongoing process.  
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ABSTRACT
Objectives: Brain-derived neurotrophic factor (BDNF) is involved in numerous cognitive proc-
esses. Since cognitive deficits are a core feature of psychotic disorders, the investigation of
BDNF levels in psychosis and their correlation with cognition has received increased attention.
However, there are no studies investigating BDNF levels in individuals with an at-risk mental
state (ARMS) for psychosis. Hence, the aims of the present study were: (1) assessing peripheral
BDNF levels across different (potential) stages of psychosis; (2) investigating their association
with cognition.
Methods: Plasma and serum BDNF levels and neuropsychological performance were assessed in
16 ARMS, six first-episode psychosis (FEP), and 11 chronic schizophrenia (CS) patients.
Neuropsychological assessment covered intelligence, verbal memory, working memory, attention
and executive functioning.
Results: Both plasma and serum BDNF levels were highest in CS, intermediate in FEP and lowest
in ARMS. Multiple regression analysis revealed a significant positive association of plasma BDNF
levels with planning ability across all groups.
Conclusions: The lower peripheral BDNF levels in ARMS compared to FEP and CS might point
towards an important drop of this neurotrophin prior to the onset of frank psychosis. The asso-
ciations of peripheral BDNF with planning-abilities match previous findings.
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1. Introduction
The presence of cognitive deficits is a consistent find-
ing in patients with psychotic disorders. These apply
to most cognitive domains including working memory,
verbal memory, executive function, attention, speed of
information processing and visuo-spatial abilities
(Fusar-Poli et al. 2012; Bora and Murray 2014; Hauser
et al. 2017), and are considered to be a core feature
of these disorders (Szoke et al. 2008).
Long-term (Agnew-Blais et al. 2015) and cross-
sectional studies (Bora et al. 2014) have shown that
cognitive impairments are present long before the
onset of overt psychotic symptoms (Riecher-R€ossler
et al. 2009; Mollon and Reichenberg 2017). However,
they do not appear to progress after the transition to
full-blown psychosis or during the further course of
the illness (Szoke et al. 2008; Bozikas and Andreou
2011; Irani et al. 2011; Bora and Murray 2014; Bora
et al. 2017). Moreover, among subjects identified as
having an at-risk mental state (ARMS) for psychosis,
those with a later transition exhibit more pronounced
neurocognitive deficits than those who will not go on
to develop a psychotic disorder (Studerus et al. 2016;
Riecher-R€ossler and Studerus 2017). However, despite
their obvious significance for psychosis prediction as
well as their importance for functional outcome, the
neurobiological underpinnings behind the observed
impairments remain largely unknown (Ruiz de Azua
et al. 2013).
Over the last years, the role of brain-derived neuro-
trophic factor (BDNF) in cognitive impairments in
patients with psychosis has become a focus of interest.
BDNF is the most common neurotrophin in the human
brain and is involved in the synthesis, differentiation,
CONTACT Anita Riecher-R€ossler anita.riecher@upkbs.ch Center for Gender Research and Early Detection, University of Basel Psychiatric Hospital,
Wilhelm Klein-Strasse 27, 4002 Basel, Switzerland
Supplemental data for this article can be accessed at https://doi.org//10.1080/15622975.2018.1462532.
 2018 Informa UK Limited, trading as Taylor & Francis Group
THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
https://doi.org/10.1080/15622975.2018.1462532
maintenance and survival of neurons, both in the cen-
tral and in the peripheral nervous system (Kuipers and
Bramham 2006). Its role in learning and memory has
previously been supported by animal (Yamada and
Nabeshima 2003; Bekinschtein et al. 2008) as well as
human studies (for a review see Carlino et al. 2013). In
line with these observations, BDNF is highly expressed
in hippocampal and prefrontal cortical areas, which are
crucial for these cognitive processes (Conner et al.
1997; Bekinschtein et al. 2008).
BDNF is also found in the peripheral nervous system
and can be assessed in blood serum and plasma.
Although the exact source of the peripheral BDNF is not
yet completely understood, animal studies have shown
that BDNF can cross the blood–brain barrier (Pan et al.
1998). Furthermore, several animal studies have
reported positive correlations between serum BDNF and
BDNF in both the prefrontal cortex and hippocampus
(Karege et al. 2002; Sartorius et al. 2009; Elfving et al.
2010), suggesting that there might be a link between
peripheral and central BDNF. Moreover, Klein et al.
(2011) reported that blood BDNF concentration reflects
brain-tissue BDNF level even across species.
Also, altered BDNF levels were found in patients
suffering from psychotic disorders. Post-mortem stud-
ies in patients with schizophrenia point towards
decreased cortical BDNF levels, especially in memory-
related brain areas such as the hippocampus (Durany
et al. 2001; Weickert et al. 2003).
Peripheral BDNF levels have also been investigated in
patients with psychosis. In drug-naïve first-episode
psychosis (FEP) patients, serum BDNF levels have also
been reported to positively correlate with BDNF levels
measured in the cerebrospinal fluid (Pillai et al. 2010).
Based on these findings, BDNF blood levels are widely
used in research as correlates of cortical BDNF. However,
so far there is no consensus whether plasma or serum
BDNF levels are more suitable correlates of cortical
BDNF levels. While some authors have suggested to use
serum as it might provide a more reliable measurement
(Tsuchimine et al. 2014), others have argued in favour of
plasma as it might better reflect processes in the central
nervous system (Fernandes et al. 2014).
In patients with psychotic disorders, recent reviews
and meta-analyses point towards reduced peripheral
BDNF levels, with peripheral levels being already
decreased in FEP patients and further declining in
chronic and accordingly older patients (Buckley et al.
2011; Green et al. 2011; Martinotti et al. 2012;
Fernandes et al. 2014; Toll and Mane 2015).
Until now, several studies have investigated the
association between cognitive impairments and BDNF
in patients with psychosis. The findings of these stud-
ies (summarized in Supplementary Table 1S) are incon-
sistent regarding the link of peripheral BDNF levels to
cognition. The majority of these studies point towards
a positive association of certain cognitive functions
with peripheral BDNF levels (Carlino et al. 2011; Niitsu
et al. 2011; Zhang, Chen et al. 2012; Zhang, Liang,
et al. 2012; Asevedo et al. 2013; Ruiz de Azua et al.
2013; Hori et al. 2016; Sun et al. 2016; Hori et al. 2017;
Zhang et al. 2018). However, other studies found
mixed results, i.e. positive and negative associations
depending on the cognitive domain (Niitsu et al. 2014;
Xiao et al. 2017). Lastly, other research groups did not
find any association between these two parameters
(Buckley et al. 2007; Goto et al. 2009; Vinogradov et al.
2009; Theleritis et al. 2014; Fisher et al. 2016; Man et
al. 2018). A recent meta-analysis concluded that there
is a small but significant positive association of periph-
eral BDNF with reasoning and problem solving, and
with overall cognitive capacity in patients with schizo-
phrenia (Ahmed et al. 2015).
Despite the strong interest in the prodromal phase
of psychosis and the above described observed onset
of cognitive deficits prior to transition to frank psych-
osis, no study has investigated peripheral BDNF levels
in an ARMS sample yet. Therefore, we aimed (1) to
investigate plasma and serum BDNF levels across
different (potential) stages of psychosis, including for
the first-time ARMS as well as FEP and chronic schizo-
phrenia (CS) patients, and (2) to examine the associ-
ation of BDNF with neurocognitive performance in
these patient groups.
Based on the above described literature, the
following hypotheses were formulated: (1) both
plasma and serum BDNF are highest in ARMS, inter-
mediate in FEP and lowest in CS; (2) higher BDNF
levels are associated with better cognitive perform-
ance in all patient groups.
2. Methods
2.1. Recruitment and setting
FEP and ARMS patients were recruited via the
Fr€uherkennung von Psychosen project (FePsy; English:
early detection of psychosis) within the University of
Basel Psychiatric Hospital (UPK), Switzerland. ARMS
and FEP criteria were assessed using the Basel
Screening Instrument for Psychosis (BSIP; Riecher-
R€ossler et al. 2008), which is based on the PACE crite-
ria (Yung et al. 1998) and includes parts of the Brief
Psychiatric Rating Scale (BPRS, expanded version by
Lukoff et al. 1986; Ventura et al. 1993). A detailed
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description of the FePsy study design can be found
elsewhere (Riecher-R€ossler et al. 2007; Riecher-R€ossler
et al. 2009). Individuals were classified as being in an
ARMS if they met one of the following inclusion crite-
ria: (1) attenuated or brief limited psychotic symptoms
according to the criteria by Yung et al. (1998); (2)
familial aggregation of psychotic disorders in combin-
ation with at least two further risk factors according to
screening instrument in line with the criteria by Yung
et al. (1998); (3) a minimal amount and combination
of certain risk factors according to screening instru-
ment by Riecher-R€ossler et al. (2007). FEP patients had
to fulfil the transition criteria of Yung et al. (1998),
namely one of the following symptoms: suspiciousness
(BPRS5), unusual thought content (BPRS5), halluci-
nations (BPRS4), or conceptual disorganisation
(BPRS5), with the symptom occurring at least several
times a week and being present for more than 1
week. Exclusion criteria were age <18 years, insuffi-
cient knowledge of German, IQ <70, previous psych-
otic episode, antipsychotic medication exceeding a
cumulative chlorpromazine equivalent (CPE) dose of
2500mg (according to Gardner et al. (2010) and
Leucht et al. (2014)), psychosis clearly due to organic
brain diseases or substance use, or psychotic symp-
tomatology within a clearly diagnosed affective psych-
osis or borderline personality disorder.
CS patients were recruited in the forensic depart-
ment of the UPK and had a diagnosis of schizophre-
nia, paranoid type according to ICD-10 criteria
(International Statistical Classification of Diseases and
Related Health Problems; World Health Organization
1994). There were no restrictions regarding comorbid-
ities or medication in this group.
Only male participants were included in the present
study, as BDNF levels can vary between the sexes and
fluctuate along the menstrual cycle (Begliuomini et al.
2007). Additionally, nicotine use was measured in ciga-
rettes per day, as nicotine has previously been found to
be associated with higher BDNF levels in clinical and
non-clinical populations (Bhang et al. 2010; Zhang et al.
2010). All participants gave their written informed con-
sent. The study was approved by the committee of
North-West and Central Switzerland (Ethikkommission
Nordwest- und Zentralschweiz (EKNZ)) and was carried
out in accordance with the declaration of Helsinki.
2.2. BDNF measures
Peripheral BDNF is mainly stored in blood platelets,
while a small part circulates freely. Therefore, we
assessed total soluble BDNF in serum, which includes
BDNF released from platelets through clotting, in add-
ition to plasma BDNF levels. For the assessment of
BDNF levels, a blood sample was drawn between 07:00
and 09:00 h after overnight fasting according to a
standardised protocol, using serum vacutainer tubes
(Becton Dickinson) or citrate vacutainer tubes (Becton
Dickinson). For serum sampling, the tube was inverted
gently five to six times and allowed to stand for 60min
at room temperature. Subsequently, it was centrifuged
at 1300 g for 10min. Regarding plasma BDNF, poor-
platelet plasma was carefully prepared from blood cen-
trifuged at 2000 g for 10min. All samples were stored
in aliquots at80 C before assaying BDNF content.
Serum and plasma BDNF levels were assessed with an
enzyme-linked immunosorbent assay (ELISA) kit
(Promega BDNF Emax, Madison, WI, USA). Serum sam-
ples were appropriately diluted (between 1:100 and
1:150), while plasma samples were used undiluted, and
detection of BDNF was carried out in an antibody sand-
wich format as described in the manufacturer’s proto-
col. The absorbance was measured within 30min in a
microplate reader set at 450 nm and a correction wave-
length set to 690 nm, to determine BDNF concentra-
tions according to the standard curve. All assays were
carried out in duplicate and means were calculated.
2.3. Neuropsychological assessment
The following measures were used to cover the cogni-
tive domains of interest:
 Verbal and non-verbal intelligence: Mehrfachwahl-
Wortschatz Test (MWT-A; Lehrl 1977) and
Leistungspr€ufsystem, scale 3 (LPS-3; Horn 1983),
respectively.
 Verbal learning and memory: California Verbal
Learning Test (CVLT; Delis et al. 1987).
 Working memory: two-back test of the Test of
Attentional Performance (TAP; Zimmermann and
Fimm 2002).
 Executive functioning: computerised version of the
Tower of Hanoi (ToH; Gedika and Sch€ottke 2001)
and Go/No-Go task of the TAP (Zimmermann and
Fimm 2002).
 Sustained attention: computerised version of the
Continuous Performance Test (CPT-OX; Rosvold
et al. 1956).
2.4. Statistical analyses
BDNF values were tested for normality and plasma levels
were log-transformed to achieve a normal distribution.
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In all subsequently described analyses, the
log-transformed plasma values were used. BDNF levels
were compared between the patient groups
(i.e. ARMS, FEP and CS) using a one-way ANOVA, with
Bonferroni-corrected post hoc pairwise comparisons. Due
to the small sample size, bootstrapping was performed
to provide more robust estimates. Subsequently, an
ANCOVA was carried out including age, CPE and ciga-
rettes per day as possible confounding factors. In case of
no antipsychotic or nicotine use, a value of 0 was used
to include these participants in the analysis.
A global neuropsychology score comprising all
tested domains was created. Furthermore, composite
scores for each test of the neuropsychological battery
were created. Variables for which high values indi-
cated worse performance (e.g. reaction times) were
inverted prior to the z-transformation, so that high val-
ues always indicated good performance. The test spe-
cific composite scores were the averages of the z-
transformed performance scores of each test. The glo-
bal cognitive performance score was the average over
all z-transformed performance scores. This procedure
was used to reduce the number of tests and hence to
reduce the risk of false-positive results due to multiple
testing. A description of this procedure can also be
found in a previous publication of our research group
(Rapp et al. 2013). An overview of the test variables
used to create the composite scores can be found in
the appendix (Supplementary Table 2S).
The composite scores were compared between
patient groups using a one-way ANOVA, with
Bonferroni-corrected post hoc comparisons. Again,
bootstrapping was performed due to the small sample
size. A second group comparison was carried out
using an ANCOVA including age and CPE as possible
confounding factors.
A Bonferroni-corrected multiple linear regression
analysis was performed to assess the associations of
group, age, years of education, CPE, and the two
BDNF measures with each neuropsychological com-
posite score.
Statistical significance was set at a 0.05. All analy-
ses were carried out using IBM SPSS Statistics Version
24 running on Windows 7 Enterprise.
3. Results
3.1. Sample characteristics
A total of 33 participants were included in this study:
16 ARMS, six FEP and 11 CS patients. The CS sample
was significantly older than the two other groups and
received higher antipsychotic dosages (see Table 1).
Nicotine use, measured in cigarettes per day, differed
significantly between groups, being highest in CS,
intermediate in FEP and lowest in ARMS individuals.
There were no significant group differences regarding
years of education.
3.2. BDNF
A significant main effect of group was found for both
plasma and serum BDNF levels (Table 2 and Figure 1).
Post hoc pairwise comparisons revealed that serum
BDNF was significantly lower in ARMS as compared to
both other groups (FEP p¼ .033; CS p< .001), while
plasma BDNF differed at a significant level only
Table 1. Sample characteristics.
Variable ARMS (n¼ 16) FEP (n¼ 6) CS (n¼ 11) Significance
Age (years) 24.56 (±5.27) 29.40 (±6.27) 38.38 (±6.63) >0.001
Years of education 12.69 (±2.80) 11.25 (±1.37) 10.91 (±1.26) 0.211a
Current use of antipsychotics (yes/no) 1/15 4/2 11/0
CPE 20 (±0) 85.00 (±88.49) 1216.78 (±987.92) 0.049b
Current use of nicotine (yes/no)c 11/5 4/2 11/0
Cigarettes per dayc 11.82 (±11.68) 15.00 (±16.58) 31.88 (±14.62) 0.044a
Note. Mean (± standard deviation).
aKruskal-Wallis test, otherwise one-way ANOVA.
bIndependent sample t-test.
cMean calculated based on those participant with current use only; antipsychotic dosage in chlorpromazine equiva-
lents (CPE); at-risk mental state (ARMS), first-episode psychosis (FEP), chronic schizophrenia (CS); not applicable (n.a.).
Table 2. BDNF level comparison between ARMS, FEP and CS patients.
BDNF (ng ml1) ARMS (n ¼ 16) FEP (n ¼ 6) CS (n ¼ 11) Significance (ANOVA) Significance (ANCOVA)c
Serum 19.11 (±4.67) 24.48 (±2.40) 28.08 (±3.99) F(2, 30)¼ 15.688; p< .001 F(2, 5)¼ 5.322; p¼ .015
Plasma 0.30 (±0.29)a 0.54 (±0.54)a 1.31 (±1.06)a F(2, 30)¼ 9.835; p¼ .001b F(2, 5)¼ 2.761; p¼ .090b
Mean (± standard deviation).
aNon-log transformed values reported.
bAnalysis carried out using the plasma log value.
cSignificance after inclusion of age, nicotine use and chlorpromazine equivalent (CPE) as covariates; brain-derived neurotrophic factor (BDNF), at-risk
mental state (ARMS), first-episode psychosis (FEP), chronic schizophrenia (CS).
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between the ARMS and CS group (p< .001), again
with lower values in the ARMS group. Plasma BDNF
levels differed at a trend level between CS and FEP
patients (p¼ .089), being lower in FEP.
After controlling for age, CPE and cigarettes per
day use, serum BDNF values still differed significantly
between the groups, while the main effect for
plasma levels was only significant at a trend level (see
Table 2). None of the included covariates had a signifi-
cant effect on BDNF parameters.
3.3. Neuropsychology
The unadjusted group comparison of the neuro-
psychological composite scores revealed significant
differences for the following tests: TAP Go/No-Go and
the CVLT (see Table 3).
Post hoc pairwise comparisons indicated that the
differences in Go/No-Go performance were due to
poorer performance of the FEP group as compared to
the other groups (ARMS p¼ .004; CS p¼ .003). The CS
Figure 1. Plasma and serum BDNF levels in ARMS, FEP and CS. BDNF: brain-derived neurotrophic factor; ARMS: at-risk mental
state for psychosis; FEP: first-episode psychosis; CS: chronic schizophrenia. Plasma and serum BDNF values are presented as non-
log transformed values (ng/ml) with mean and 95% confidence intervals of the mean.
Table 3. Neuropsychological composite score comparison between ARMS, FEP and CS.
Variable ARMS (n¼ 13) FEP (n¼ 5) CS (n¼ 9) Significance (ANOVA) Significance (ANCOVA)a
IQ 0.12 (±0.78) –0.37 (±0.61) –0.25 (±0.87) F(2, 24)¼ 1.027; p¼ .373 F(4, 25)¼ 1.041; p¼ .409
ToH –0.04 (±0.56) –0.66 (±1.11) 0.25 (±0.85) F(2, 24)¼ 2.176; p¼ .135 F(4, 25)¼ 1.226; p¼ .330
TAP Go/No-Go 0.18 (±0.55) –0.93 (±0.95) 0.29 (±0.33) F(2, 24)¼ 8.171; p¼ .002 F(4, 25)¼ 3.529; p¼ .024
TAP WM 0.02 (±0.77) 0.07 (±0.82) –0.05 (±0.43) F(2, 24)¼ 0.019; p¼ .981 F(4, 25)¼ 0.134; p¼ .968
CPT 0.12 (±0.47) 0.17 (±0.39) –0.23 (±0.84) F(2, 24)¼ 1.027; p¼ .373 F(4, 25)¼ 0.807; p¼ .535
CVLT 0.42 (±0.63) 0.36 (±0.94) –0.71 (±0.84) F(2, 24)¼ 6.402; p¼ .006 F(4, 25)¼ 2.744; p¼ .056
Global 0.13 (±0.3) –0.24 (±0.43) –0.08 (±0.38) F(2, 24)¼ 1.881; p¼ .174 F(4, 25)¼ 0.952; p¼ .454
Mean (± standard deviation).Significant at p< .05.
aIncluding age and chlorpromazine equivalent as covariate; at-risk mental state (ARMS), first-episode psychosis (FEP) and chronic schizophrenia (CS).
Table 4. Multiple regression.
Predictor Global IQ ToH TAP Go/No-Go TAP WM CPT CVLT
Group –0.241 (192) –0.137 (0.375) –0.028 (0.392) 0.039 (0.340) 0.422 (0.362) –0.875 (0.302) –0.505 (0.375)
Age –0.289 (0.015) 0.303 (0.030) –0.328 (0.029) 0.153 (0.027) –0.434 (0.029) 0.055 (0.024) –0.343 (0.030)
Years of education 0.073 (0.038) 0.219 (0.074) –0.153 (0.072) 0.408 (0.066) –0.063 (0.071) –0.124 (0.059) 0.060 (0.072)
CPE –0.116 (0.000) –0.095 (0.000) 0.023 (0.000) 0.241 (0.000) –0.381 (0.000) 0.100 (0.000) –0.116 (0.000)
Serum BDNF –0.230 (0.022) –0.148 (0.043) –0.435 (0.042) –0.312 (0.040) –0.376 (0.041) 0.252 (0.036) 0.404 (0.044)
Plasma BDNF 0.560 (0.150) –0.042 (0.205) 0.804 (0.201) o.132 (0.183) 0.298 (0.198) 0.406 (0.163) 0.026 (0.202)
Standardized coefficient (standard error).Significant at p< .05; trend at p< .1.
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group performed worse in the CVLT than the other
groups (ARMS p¼ .007; FEP p¼ .058).
After including age as covariate, only the main effect
for the TAP Go/No-Go remained significant (p¼ .003).
3.4. Multiple regression
The results of the multiple regressions can be found
in Table 4. There was a significant positive association
between plasma BDNF and ToH performance
(p¼ .015) and trend-wise significant positive associ-
ation between plasma BDNF and global cognitive per-
formance (p¼ .071).
4. Discussion
In this cross-sectional study we found that plasma and
serum BDNF levels differed between ARMS, FEP and
CS patients, with the highest levels being evident in
CS and the lowest in ARMS patients. Moreover, higher
plasma BDNF levels were significantly associated with
better ToH performance and at a trend-level with a
better global cognitive performance score.
The observed pattern regarding peripheral BDNF
levels contradicts the existing literature (Green et al.
2011; Martinotti et al. 2012) as well as our hypothesis
of higher BDNF levels in ARMS and a decrease over
the course of illness. In the present study, serum
BDNF levels were significantly lower in ARMS patients
compared to both other groups, but did not differ
between FEP and CS patients. Plasma levels were only
significantly lower in ARMS compared to CS patients.
Unfortunately, we were not able to differentiate fur-
ther between those ARMS patients who transitioned
to psychosis and those who did not; therefore, it is
not possible to interpret the observed pattern regard-
ing transition to psychosis and hence the presence of
a true prodromal state. Based on the present findings
it might be speculated that the low peripheral BDNF
levels in ARMS patients are associated with the clinical
observation of a drop in functioning prior to the onset
of frank psychosis, including poorer cognitive perform-
ance which occurs already in the pre-psychotic phase
(Riecher-R€ossler et al. 2009; Bora and Murray 2014).
This might imply that the low BDNF levels in ARMS
point towards pathological processes preceding the
actual transition to psychosis. It might be possible
that, during the course of the illness and possibly due
to the (pharmacological) treatment of psychotic disor-
ders, BDNF levels normalise while cognitive deficits
persist, as the latter have been suggested by meta-
analyses of longitudinal studies (Irani et al. 2011; Bora
and Murray 2014). However, as this is the first study to
investigate peripheral BDNF levels in ARMS individuals,
more research is needed before any firm conclusions
can be drawn.
The factors leading to altered BDNF levels in
patients with psychotic disorders are still under
debate. A review by Martinotti et al. (2012) revealed
higher peripheral BDNF levels in patients suffering
from paranoid psychosis compared to other psychotic
subtypes. As the CS sample in the present study con-
sisted only of patients with such a diagnosis, the
higher plasma and serum BDNF levels in the CS group
might partly be related to this factor. The restriction
to the paranoid type in our study was made to reduce
the variability in this patient group and to avoid a
potential symptomatic overlap between depressive
symptoms and negative symptoms, the latter being
more present in other types of schizophrenia, since
peripheral BDNF levels are also altered in patients
with depression (Molendijk et al. 2014).
Contrary to previous studies (Zhang et al. 2010;
Green et al. 2011) that reported an influence of age
and nicotine on BDNF levels, these factors were not
found to influence BDNF in the present study.
Regarding medication, the observed lack of effect on
BDNF levels in our study is in line with the meta-ana-
lysis of Green et al. (2011). However, in the more
recent meta-analysis of Fernandes et al. (2014), the
authors found an increase of BDNF in plasma but not
in serum after antipsychotic medication, independent
of the patient’s response to the treatment. In our
study, the inclusion of CPE reduced the significance to
a trend level in plasma but not in serum. It might be
speculated that plasma levels react more sensitively to
antipsychotic treatment, but clearly more research is
needed before any firm conclusions can be drawn. It
should, however, be mentioned that it is still possible
that these factors do influence BDNF levels, and that
the present sample was too small to detect this asso-
ciation. We can, therefore, not completely rule out the
possibility that the unexpectedly higher BDNF levels in
the CS group compared to ARMS and FEP patients
was influenced by the higher medication dosage and
longer medication intake with a larger cumulative
medication dose in the chronic patients.
Plasma BDNF levels were significantly and positively
associated with ToH performance and at a trend-level
with global cognitive performance, which is in line
with our hypothesis and with most previous reports
investigating the association of peripheral BDNF levels
with neurocognitive performances. A recent meta-ana-
lysis (Ahmed et al. 2015) also indicated a positive asso-
ciation of peripheral BDNF levels with neurocognition
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in patients with schizophrenia. In the meta-analysis,
higher BDNF levels were associated with better per-
formance in reasoning/problem solving and with over-
all performance across all neurocognitive measures.
However, the authors suggested that the association
with combined neurocognitive measures was driven
by the positive association of BDNF levels with reason-
ing/problem solving. A similar pattern could also
underlie the present results.
Due to its exploratory character, the present study
suffers from certain limitations. First, the small sample
size limits statistical power, which might have
impeded the detection of group differences, and pre-
vented further subgroup analyses. Second, no healthy
control or clinical control groups were included.
Therefore, the specificity of the results for psychosis
cannot be clarified, especially as altered BDNF levels
have also been found in other psychiatric disorders
such as depression, bipolar disorder and anorexia (for
a review see Cattaneo et al. 2016). Furthermore, BDNF
levels in healthy control groups vary considerably
across studies due to methodological differences
(Green et al. 2011), so that the present BDNF levels
cannot be compared to previous reports. Third, many
factors that are known to affect BDNF levels, such as
antidepressant medication (Polyakova et al. 2015),
sleep deprivation (Guzman-Marin et al. 2006), stress
(Giese et al. 2013), body weight (Pillai et al. 2012),
drug consumption (D'Souza et al. 2009) or physical
exercise (Dinoff et al. 2017) were not assessed in the
present study. However, we tried to account for the
most important confounding factors, namely age,
years of education, nicotine use and antipsychotics.
Fourth, the cross-sectional design limits the interpret-
ability of the findings. Longitudinal studies are war-
ranted to investigate the time course of BDNF levels
across different stages of psychosis.
Strengths of the present study should also be men-
tioned, especially the inclusion of innovative elements
that led to new insights. First, this is the first study to
investigate BDNF levels in an ARMS sample. The pat-
tern of results indicates that it is vital to further study
peripheral BDNF levels in this patient population, to
promote understanding of the biological underpin-
nings of clinical and cognitive processes preceding the
onset of frank psychosis. A second strength of this
study is the simultaneous analysis of plasma and
serum BDNF, considering that there is no consensus
so far as to which of the two parameters is a more
suitable peripheral biomarker. Our results indicate that
the free circulating plasma BDNF may be more closely
associated with cognitive performance and should
therefore be considered in future investigations.
In summary, the present study observed lower
serum and plasma BDNF levels in ARMS patients com-
pared to FEP and CS. This finding, although unex-
pected at first glance, might point towards an
important pathological process prior to the onset of
full-blown psychosis. The observed positive correlation
between plasma BDNF and executive functions might
provide a link to the well-established cognitive deficits
of psychotic disorders, which are already present in
the ARMS.
Regarding the potential implications of our study
for the field of early detection, the surprisingly low
peripheral BDNF levels in ARMS patients might be a
valuable further marker to detect individuals at-risk for
psychosis which might, in combination with other
markers, improve the accuracy of early detection.
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an overnight fast and 30 minutes of rest. All patients were antipsychotic-naïve and did not take any prolactin
influencing medication.
Results: Our sample consisted of 116 antipsychotic-naïve ARMS and 49 FEP patients. Hyperprolactinemia was
shown in 32% of ARMS and 35% of FEP patients. After correction for the normal biological variation between
the sexes, we still found higher average prolactin levels in female than in male patients (β= 0.42; t = 2.47;
p = 0.01) but no difference in prolactin levels between ARMS and FEP patients (β=−0.05; t =−0.30; p =
0.76). The survival analysis revealed no significant predictive value for prolactin levels to predict transition to
psychosis.
Conclusion:Ourfindings support a possible role of prolactin in emerging psychosis and it could be speculated that
stress, which can induce hyperprolactinemia, has a stronger effect on women than on men in emerging
psychosis.
© 2017 Published by Elsevier B.V.Keywords:
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Clinical high-risk1. Introduction
Prolactin is a polypeptide hormone that is predominantly synthe-
sized and secreted by lactotroph cells of the anterior pituitary gland.
While its main function is to elicit lactation in mammals (Fitzgerald
and Dinan, 2008), it is also involved in a broad spectrum of functions
beyond reproduction and lactation. Most importantly, it is also released
in response to psychosocial stress (Fitzgerald and Dinan, 2008;
Lennartsson and Jonsdottir, 2011). There is compelling epidemiological
evidence that psychosocial stress is implicated in the development of
psychotic symptoms (Aiello et al., 2012; van Winkel et al., 2008).
Previous research has shown an association between cortisol levels
and severity of positive and nonspecific symptoms (Aiello et al., 2012;
Holtzman et al., 2013; Walker et al., 2013), as well as correlationstric Hospital, Center for Gender
el, Switzerland.
ssler).
differences in prolactin level
i.org/10.1016/j.schres.2017.0between the stress hormone prolactin and psychopathological symp-
toms (Rajkumar, 2014).
Themain regulatorymechanism acting on prolactin is the inhibition
of prolactin synthesis by dopamine. Dopamine itself is synthesized in
neurons of the hypothalamus and then secreted through portal blood
into the anterior pituitary where it exerts its inhibitory actions on
prolactin-producing cells through D2 receptors. Dopamine is thus the
main prolactin inhibiting factor (PIF) (Fitzgerald and Dinan, 2008). On
the other hand, dopaminergic neurotransmission plays an important
role in the pathophysiology of schizophrenic psychoses (Howes et al.,
2009) which was inferred from the link between the antipsychotic
efficacy of neuroleptic drugs and their affinity for the dopaminergic D2 re-
ceptor (Bennett, 1998). Hence, hyperprolactinemia is often described as a
side effect of antipsychotics in patients with schizophrenic psychoses
(Peuskens et al., 2014). However, there have also been recent reports on
hyperprolactinemia in antipsychotic-naïve FEP and ARMS patients.
Hyperprolactinemia in these patients could probably be explained by
psychosocial stress (Riecher-Rössler et al., 2013), as it is implicated in
the development of psychotic symptoms (van Winkel et al., 2008) ands in emerging psychosis: Indication for enhanced stress reactivity in
2.010
2 S. Ittig et al. / Schizophrenia Research xxx (2017) xxx–xxxknown to stimulate prolactin synthesis and release (Lennartsson and
Jonsdottir, 2011). Riecher-Rössler et al. (2013) suggested that stress in-
duces hyperprolactinemia and the resulting increase of dopamine in psy-
chosismight be, at least in part, a regulatorymechanism to down regulate
prolactin. The European First Episode Schizophrenia Trial (EUFEST)
(Riecher-Rössler et al., 2013) found elevated prolactin levels in 40.5% of
antipsychotic-naïve FEP patients. In a further study by Aston et al.
(2010) hyperprolactinemia was found in 33.3% of antipsychotic-naïve
FEP patients and even in 23.8% of ARMS patients. A recent meta-analysis
(Gonzalez-Blanco et al., 2016) reported higher prolactin levels in antipsy-
chotic-naïve male and female patients with schizophrenia compared to
control groups of the same gender, although the effect was much more
pronounced inmen than inwomen. A recent study also foundhigher pro-
lactin serum levels in drug naïve newly diagnosed patients with schizo-
phrenia and other psychotic disorders compared to HC (Petrikis et al.,
2016). Furthermore, Labad et al. (2015) showed that ARMS patients
who later made a transition to psychosis (ARMS-T) had higher prolactin
levels than those who did not (ARMS-NT). Moreover, one study conduct-
ed in patients with pituitary microadenoma (Cheng et al., 2013) showed
significantly higher prolactin serum levels in antipsychotic-naïve patients
with a pituitary microadenomawith psychosis than in patients with a pi-
tuitary microadenoma without psychosis. All these findings provide fur-
ther evidence for an association of elevated prolactin levels and psychosis.
To further elucidate the role of prolactin in emerging psychosis we
formulated the following hypotheses based on previous findings. We
expected I) increased frequencies of hyperprolactinemia in ARMS and
FEP patients (Aston et al., 2010), II) higher prolactin levels in FEP as
compared to ARMS patients, and III) more elevated prolactin levels in
men than in women (Gonzalez-Blanco et al., 2016). Moreover, as pro-
lactin is also a stress hormone and stress is thought to have an influence
on psychopathology (Aiello et al., 2012; Holtzman et al., 2013; Walker
et al., 2013) we hypothesized to find IV) a positive association of prolac-
tin with psychopathological symptoms and V) higher baseline prolactin
levels being predictive of transition to psychosis in ARMS patients.
2. Methods
2.1. Setting and recruitment
The data analysed in this study were collected within the prospec-
tive Früherkennung von Psychosen (FePsy) study, which aims to im-
prove the early detection of psychosis. A more detailed description of
the overall study design can be found elsewhere (Riecher-Rössler et
al., 2007; Riecher-Rössler et al., 2009). Participants were recruited for
the study via the FePsy Clinic at the Psychiatric University Outpatient
Department of the Psychiatric University Hospital Basel, which was set
up specifically to identify and treat individuals in the early stages of
emerging psychosis.
The studywas approved by the ethics committee of the University of
Basel and all participants provided written informed consent.
2.2. Screening procedure
Screening was performed with the Basel Screening Instrument for
Psychosis (Riecher-Rössler et al., 2008). This instrument allows the rat-
ing of individuals regarding the inclusion/exclusion criteria correspond-
ing to the Personal Assessment and Crisis Evaluation (PACE) criteria
(Yung et al., 2007; Yung et al., 1998) and has been shown to have a
good interrater reliability (κ=0.67) for the assessment of themain out-
come category “at risk for psychosis” and a high predictive validity
(Riecher-Rössler et al., 2008). Individuals were classified as being in
an ARMS for psychosis, having a FEP, or being not at risk for psychosis
(usually other psychiatric disorders).
For this study we included all ARMS and FEP patients that were re-
cruited for the FePsy study from March 1, 2000 to February 29, 2016
who had undergone prolactin measurement. We excluded all patientsPlease cite this article as: Ittig, S., et al., Sex differences in prolactin level
women, Schizophr. Res. (2017), http://dx.doi.org/10.1016/j.schres.2017.0whohad ever taken antipsychotics or any prolactin-influencingmedica-
tion at the time of assessment (i.e. hormonal contraception). Likewise,
we excluded all patients with a medical condition potentially influenc-
ing prolactin status, such as hypothyroidism or pituitary abnormalities
or in whom blood sampling and psychopathological assessment were
N60 days apart.
All ARMS patients were followed-up at regular intervals for up to
5 years (in the first year monthly, second and third year 3-monthly
and the last two years every year) (Riecher-Rössler et al., 2009) in
order to distinguish those who later transitioned to frank psychosis
(ARMS-T) from those who did not (ARMS-NT) using the transition
criteria of Yung et al. (1998).
2.3. Prolactin measurement
The patients were asked to avoid stress, sports, physical activity,
stimulation of breast and smoking during the last 12 h before blood
sampling. Blood sample collection took place between 8 and 10 am
after overnight fast and 30 min of rest (7.5 ml whole blood without
any additions).
The ElectroChemiLuminescence ImmunoAssay “ECLIA” (Ref. Num-
ber 03203093 190, Roche Diagnostics GmbH D-68305 Mannheim)
was used to measure prolactin levels. The method has been standard-
ized against the 3rd IRP WHO Reference Standard 84/500 and
hyperprolactinemia in this reference is defined as a value above the
97.5th percentile, that is N324 mU/l in men and N496 mU/l in women.
2.4. Psychopathological assessment
The Brief Psychiatric Rating Scale Expanded Version (BPRS-E)
(Lukoff et al., 1986; Ventura et al., 1993)wasused to assess positive psy-
chotic symptoms, symptoms of depression/anxiety, negative symptoms
as well as symptoms of activation as defined by Velligan et al. (2005).
2.5. Statistical analyses
All data were analysed using the R environment for statistical com-
puting (R Core Team, 2015). Differences in sociodemographic and clin-
ical characteristics between ARMS and FEP patients were tested with t
and χ2 tests. Prolactin was analysed both on a continuous and binary
scale (above reference range of corresponding sex vs. within normal
range) using linear and logistic regression models, respectively. In
both models, prolactin served as dependent variable and group (ARMS
vs. FEP) and sex (men, women) as independent variables. The models
also included an interaction term between group and sex. When
analysed on a continuous scale, prolactin values were first log-trans-
formed (to accommodate positive skew) and then normalized for men
and women separately based on the log transformed reference ranges
for healthymen andwomen. Themeans and SDs of the log transformed
normative samples for men and women were calculated by taking the
means of log transformed upper and lower bounds of the reference
ranges and by dividing the differences between log transformed upper
and lower bounds of the reference ranges by 3.92, respectively. Thus,
the normal sex difference in prolactin seen in healthy individuals was
partialled out from our continuous prolactin measure before inclusion
to the models.
To analyse the relationship between prolactin, group (ARMS, FEP)
and psychopathology, linear regression models were performed with
the four BPRS composite scores (see psychopathological assessment)
serving as dependent variables. All continuous variables were centered
and all analyses were performed with and without covariates (age and
current use of antidepressants). Furthermore, p-values were adjusted
for multiple testing using the Benjamini-Hochberg method (Benjamini
and Hochberg, 1995).
Finally, to test whether prolactin is predictive of later transition to
psychosis (event) in the ARMS group and whether its association withs in emerging psychosis: Indication for enhanced stress reactivity in
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Table 1
Socio-demographic and clinical sample characteristics.
Total group ARMS FEP p-Value
N = 165 N = 116 N = 49
Gender 1.000
Women 49 (29.7%) 34 (29.3%) 15 (30.6%)
Men 116 (70.3%) 82 (70.7%) 34 (69.4%)
Age 26.1 (6.90) 25.1 (6.16) 28.4 (7.99) 0.011*
Years of education 11.6 (2.97) 11.5 (2.90) 11.7 (3.14) 0.774
Antidepressants ever 48 (29.1%) 42 (36.2%) 6 (12.2%) 0.004**
Antidepressants currently 41 (24.8%) 35 (30.2%) 6 (12.2%) 0.025*
Anxiolytics ever 31 (18.8%) 25 (21.6%) 6 (12.2%) 0.238
Anxiolytics currently 26 (15.8%) 20 (17.2%) 6 (12.2%) 0.568
BPRS Depression/Anxiety 9.38 (3.77) 8.81 (3.46) 10.8 (4.17) 0.007**
BPRS Psychosis/Thought Disturbance 7.56 (3.77) 6.05 (2.30) 11.3 (4.11) b0.001***
BPRS Activation 5.79 (2.33) 5.39 (1.84) 6.75 (3.04) 0.008**
BPRS Negative Symptoms 5.33 (2.73) 4.95 (2.44) 6.26 (3.18) 0.017*
BPRS Total Score 42.0 (12.3) 37.8 (9.30) 52.4 (12.5) b0.001***
ARMS = at-risk mental state; FEP = first episode psychosis; BPRS = brief psychiatric rating scale; *p b 0.05; **p b 0.01, ***p b 0.001; continuous variables are described by means and
standard deviation in parentheses.
3S. Ittig et al. / Schizophrenia Research xxx (2017) xxx–xxxlater transition is different formen andwomen, survival analysis using a
Cox proportional hazard model was performed. For this purpose, all
ARMS patients regardless of their follow-up duration were included in
the analyses since survival analyses take into account censored observa-
tions (no event during observation time). The Cox regression model in-
cluded time to transition as dependent variable and prolactin (log-
transformed and normalized) and sex and their interaction as predic-
tors. Age and current use of antidepressants served as covariates in
our model.
3. Results
3.1. Sample description
181 ARMS and 132 FEP patients were recruited for the FePsy study
from March 1, 2000 to February 29, 2016. Because of missing prolactin
measurements we excluded 46 ARMS and 53 FEP patients. Further, we
excluded 19 ARMS and 30 FEP patients either because of lifetime anti-
psychotic medication, current hormonal contraception, any other cur-
rent prolactin influencing medication or because blood sampling
and psychopathological assessment were N60 days apart. Thus, we
performed the analyses on the remaining sample consisting of 116
ARMS and 49 FEP patients. The excluded individuals did not differ
from those included with regard to sex, age, years of education and
BPRS total score. The mean difference between the assessment of the
BPRS and blood sample collection was 8.18 days (S.D. = 9.52).
Sociodemographic as well as clinical characteristics of the included
individuals are presented in Table 1.
3.2. Hyperprolactinemia in ARMS and FEP patients
Hyperprolactinemia, i.e. blood levels higher than the normal range,
was present in 32% of ARMS (28% of men and 41% of women) and 35%
of FEP patients (26% of men, 53% of women) (Table 2).Table 2
Hyperprolactinemia and normalized prolactin values in antipsychotic-naive ARMS and FEP pat
ARMS
Men (n = 82) Women (n =
Proportion of patients with hyperprolactinemia, n (%) 23 (28) 14 (41)
Prolactin normalized
Mean ± S.D. 1.201 ± 1.481 1.766 ± 1.45
Median 1.188 1.723
Range −2.526–5.103 −1.104–4.47
ARMS = at-risk mental state; FEP = first episode psychosis.
S.D., standard deviation.
Please cite this article as: Ittig, S., et al., Sex differences in prolactin level
women, Schizophr. Res. (2017), http://dx.doi.org/10.1016/j.schres.2017.03.3. Effect of sex and patient group on prolactin levels
When prolactin was analysed on a continuous scale, there was a
significant main effect of sex (β=0.35; t= 2.47; p=0.01) but no sig-
nificant main effect of group (ARMS vs. FEP) (β=−0.04; t =−0.30;
p = 0.76) and no significant interaction between sex and group
(β=−0.07; t=−0.48; p= 0.63). The main effect of sex was due to
significantly higher average prolactin levels in female than in male pa-
tients even after correction for the normal sex difference in prolactin
levels of healthy individuals.
Prolactin values in ARMS and FEP patients subdivided in men and
women are displayed in Fig. 1. For the means, S.D., median and range
of the normalized prolactin values per patient group (ARMS/FEP) and
sex (men/women) see Table 2.
When prolactinwas analysed on a binary scale (Hyperprolactinemia
vs. normal prolactin values), there was again a significantmain effect of
sex (β= 0.44; z= 2.25; p= 0.02), no significant main effect of group
(β=−0.10; z =−0.53; p = 0.60) and no significant interaction be-
tween sex and group (β= −0.14; z =−0.74; p = 0.46), indicating
that hyperprolactinemia was more frequent in female than in male pa-
tients independent of diagnostic group.
When repeating the analyses with covariates age and antidepres-
sants the results did not change.
3.4. Effects of prolactin and patient group on psychopathology
For each BPRS subscale (Total, Psychosis/Thought Disturbance, De-
pression/Anxiety, Negative Symptoms, Activation) there was a signifi-
cant main effect of patient group, which was due to more severe
psychopathology in FEP compared to ARMS patients (see Table 3).
However, therewere no significantmain effects of prolactin on these
BPRS subscales and no significant interactions between prolactin and
diagnostic group (ARMS/FEP) after correction for multiple testing (see
Table 3, also for uncorrected values). When repeating the analysesients.
FEP
34) Total (n = 116) Men (n = 34) Women (n = 15) Total (n = 49)
37 (32) 9 (26) 8 (53) 17 (35)
1 1.366 ± 1.489 1.150 ± 1.695 1.989 ± 1.601 1.407 ± 1.696
1.355 0.787 2.043 1.507
6 −2.526–5.103 −2.398–5.265 −0.962–4.104 −2.398–5.265
s in emerging psychosis: Indication for enhanced stress reactivity in
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Fig. 1. Prolactin serum levels in ARMS and FEP patients subdivided by sex. The dotted
horizontal lines represent the upper and lower reference levels for men and women.
ARMS = at-risk mental state; FEP = first episode psychosis.
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4 S. Ittig et al. / Schizophrenia Research xxx (2017) xxx–xxxwith the covariates age and antidepressants the results did not change
substantially (see Table 3).
3.5. Prolactin as predictor of transition to psychosis
To investigate if prolactin values can predict later transition to psy-
chosis and if the predictive value is different for men and women, we
conducted a survival analysis within the ARMS group (n=116, number
of events 23, follow-up duration ARMS-NT: mean = 2.99 years, SD =
0.19, follow-up duration ARMS-T: mean= 1.24, S.D. = 0.32). The anal-
yses revealed no significant predictive value of prolactin levels and no
interaction effect with the variable sex (see Table 4).
4. Discussion
In this study, the role of prolactin was investigated in 116 antipsy-
chotic-naïve ARMS and 49 antipsychotic-naïve FEP patients. In line
with our hypothesis, we could replicate the finding of an increased
percentage of patients suffering from hyperprolactinemia in antipsy-
chotic-naïve ARMS and FEP patients even when blood was taken
under controlled conditions and rigorous exclusion criteria were ap-
plied. Furthermore, we found that prolactin was more increased in
women than in men after correction for the normal biological variation
between the sexes. Contrary to our hypotheses, we could not show a
difference in prolactin levels between ARMS and FEP patients; prolactin
was not significantly associated with any BPRS subscale and none of
these associations were moderated by patient group (ARMS, FEP).
Moreover, prolactin was not a significant predictor of transition to
psychosis.
While only 2.5% of people in the normal population are expected
to fulfil criteria for hyperprolactinemia according to our reference
standard, we found in our sample of antipsychotic-naïve ARMS
and FEP patients that 32% of ARMS and 35% of FEP suffered from
hyperprolactinemia. Similarly high proportions have been reported in
previous studies (Aston et al., 2010; Riecher-Rössler et al., 2013).
Hyperprolactinemia requires clinical attention because it can have se-
vere consequences, including amenorrhea, galactorrhea, an acceleration
of osteoporosis inwomen and a lack of libido and erectile dysfunction in
men (Rajkumar, 2014; Rubio-Abadal et al., 2016). These consequencesPlease cite this article as: Ittig, S., et al., Sex differences in prolactin levels in emerging psychosis: Indication for enhanced stress reactivity in
women, Schizophr. Res. (2017), http://dx.doi.org/10.1016/j.schres.2017.02.010
Table 4
Prolactin as potential predictor of transition to psychosis - Cox proportional hazardmodel.
Hazard ratio 95% CI p
Prolactin normalized 1.151 0.737–1.798 0.536
Prolactin normalized ∗ sex 1.095 0.690–1.739 0.699
Sex 1.078 0.679–1.710 0.749
Age 1.037 0.980–1.098 0.204
Antidepressants currently 1.281 0.794–2.065 0.31
CI = confidence interval.
5S. Ittig et al. / Schizophrenia Research xxx (2017) xxx–xxxare often attributed to antipsychotics and can be a reason for non-compli-
ant behaviour. Thus, it is of utmost importance tomeasure prolactin levels
before treatment to reveal a possible pre-existing hyperprolactinemia.
Contrary to the meta-analysis of Gonzalez-Blanco et al. (2016) we
found higher normalized prolactin levels and more frequent
hyperprolactinemia in women than in men. Gonzalez-Blanco did only
include studies with a healthy control group and therefore disregarded
an important study in the field. Riecher-Rössler and the EUFEST study
group (2013) found hyperprolactinemia to be present in 50% of antipsy-
chotic-naïve female FEP patients but only in 36.5% of antipsychotic-
naïve male FEP patients. Our finding of higher prolactin levels in
women is also supported by a study of Lennartsson and Jonsdottir
(2011) who demonstrated that women showed stronger prolactin re-
sponses to the Trier Social Stress Test (TSST; Kirschbaumet al., 1993), al-
beit only at a trend-level.
Our finding of a non-significant difference in prolactin levels be-
tween ARMS and FEP patients is in agreement with the only other
study that compared prolactin levels between ARMS and FEP patients
(Montalvo et al., 2014). This could indicate that stress levels are not
higher in FEP than in ARMS patients. On the other hand, studies investi-
gating the stress hormone cortisol have reported higher levels in FEP
than in ARMS patients (Aiello et al., 2012; Holtzman et al., 2013;
Walker et al., 2013). In a similar vein, our finding of non-significant as-
sociations between prolactin and BPRS subscales is difficult to reconcile
with previous research which has shown an association between the
stress hormone cortisol and the severity of positive and nonspecific
symptoms (Aiello et al., 2012; Holtzman et al., 2013; Walker et al.,
2013). However, it is consistent with our finding of no difference in pro-
lactin levels between ARMS and FEP patients and with a study of
Shrivastava and Tamhane (2000)whodid notfindan association of pro-
lactin with BPRS (although their study had a small sample size: men;
N=19, women; N=8). Further studies are needed to clarify the asso-
ciation between prolactin and psychopathological symptoms.
Although we could not confirm that prolactin is predictive of transi-
tion to psychosis, this result is consistent with Perkins et al. (2015) who
measured expression of plasma analytes reflecting inflammation,
oxidative stress, hormones and metabolism in a sample of 72 ARMS
patients and found that prolactin was not selected as a predictor of
transition to psychosis by a machine learning algorithm. However,
contradictory results were found by Labad et al. (2015). Therefore, on
the basis of the above described studies no definite conclusion can be
drawn.
A limitation of our study is that blood sampling did not take place on
the same day as the psychopathological assessment, and probably not at
time of peak symptom severity. Thus, prolactin levels may have not en-
tirely reflected stress levels at the time of psychopathological symptom
assessment. Future studies should also assess individual perceived
stress levels using, for example, the perceived stress scale (Cohen et
al., 1983), ideally at the time of psychopathological assessment and at
the time of blood sampling. The question whether elevated prolactin
levels are specific for emerging psychosis or rather generally associated
with emerging illness (e.g. depression etc.) still remains. Hence, recruit-
ment of control groups (e.g. depressive controls but also healthy con-
trols) would help to further clarify the role of prolactin in emerging
psychosis.Please cite this article as: Ittig, S., et al., Sex differences in prolactin level
women, Schizophr. Res. (2017), http://dx.doi.org/10.1016/j.schres.2017.0Taken together, our results provide further evidence for frequent
hyperprolactinemia in emerging psychosis and that this can be ob-
served in antipsychotic-naïve patients (ARMS, FEP). Moreover, women
in our patient sample (ARMS, FEP) had higher prolactin levels even
after correction for the normal biological variation, which potentially
provides an indication for a sex dependent stress reaction regarding
the hormone prolactin.
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Aim: Gender differences in the current symptomatology of patients with psychotic disorders
have previously been described in the literature. However, it has not yet been investigated
whether gender differences exist in the very first self-perceived signs or symptoms of illness
onset. The aim of this study was to investigate this aspect in at-risk mental state (ARMS) and
first-episode psychosis (FEP) patients.
Methods: ARMS and FEP were recruited via the early detection of psychosis (FePsy) clinic
Basel, Switzerland. The Basel Interview for Psychosis (BIP) was used to retrospectively assess
the first 3 self-perceived signs and symptoms at illness onset. Differences between gender and
patient groups on single item and symptom cluster levels were analysed using logistic regres-
sion models.
Results: One-hundred-thirty six ARMS (91 men, 45 women) and 89 FEP patients (63 men,
26 women) could be recruited for this study. On a single item level, women more frequently
reported “unusual anxiety, fears” and men (at a trend level) “social withdrawal” as being among
their 3 first self-perceived symptoms, independent of diagnostic group. On the symptom clus-
ter level, women more frequently reported “increased worrying/anxiety” and (sub-threshold)
“hallucinations”, independent of diagnostic group. Problems with “thinking, concentration” were
reported more frequently by men in the ARMS group only.
Conclusion: Our results suggest that only few and relatively small gender differences exist in
the first self-perceived signs and symptoms. While men initially mainly notice negative/cogni-
tive symptoms, women first notice (sub-threshold) positive and affective symptoms.
KEYWORDS
BIP, gender, prodromal, psychopathology, psychotic disorder
1 | INTRODUCTION
Gender differences in schizophrenic psychoses have long been
reported and debated. Among the most replicated findings are differ-
ences in age of onset, which is earlier in men, while women have a
second peak of illness onset around menopause (Eranti, MacCabe,
Bundy, & Murray, 2013; Häfner, Maurer, Löffler, & Riecher-Rössler,
1993; Häfner, Riecher-Rössler, Fätkenheuer et al., 1991; Häfner,
Riecher-Rössler, Maurer et al., 1991)—a pattern suggested to be due
to the protective effects of high oestrogen levels in women before
menopause (Häfner, Riecher-Rössler, Maurer et al., 1991; Häfner,
Riecher-Rössler et al., 1993; Riecher-Rössler, 2017). Additionally,
recent reviews indicate a slightly increased incidence of schizophrenic
psychoses in men compared to women (van der Werf et al., 2014).
Moreover, men have been found to abuse substances more fre-
quently and to have less illness insight, worse treatment adherence
and poorer functional and social outcome (Abel, Drake, & Goldstein,
2010; Ochoa, Usall, Cobo, Labad, & Kulkarni, 2012). Gender differ-
ences have also been reported with respect to symptomatology,
although results in this area are inconsistent: While some studies
Received: 14 November 2016 Revised: 22 August 2017 Accepted: 8 November 2017
DOI: 10.1111/eip.12528
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point towards more negative and cognitive symptoms in men and
more affective and positive psychotic symptoms in women (for an
overview see for example Waford et al., 2015), other studies either
could not confirm any gender differences (Barajas, Banos, & Ochoa,
2007; Bertani et al., 2012; Häfner, Riecher-Rössler, Fätkenheuer
et al., 1991) or found only few differences regarding illness behaviour
(Häfner, Riecher-Rössler, Fätkenheuer et al., 1991; Häfner, Riecher-
Rössler, Maurer et al., 1991).
In patients with an at-risk mental state (ARMS) for developing a
psychotic disorder, few studies have looked into potential gender differ-
ences in current symptomatology. A recent review by Barajas, Ochoa,
Obiols, and Lalucat-Jo (2015) concluded that gender differences are at
the most modest, the most replicated finding being more negative
symptoms in men. However, this conclusion was based on just 4 original
studies investigating gender differences regarding psychopathology pub-
lished up to that point (Cocchi et al., 2014; Corcoran et al., 2011;
Lemos-Giraldez et al., 2009; Willhite et al., 2008). Since then, further
studies have been published. A study by our own group (Gonzalez-
Rodriguez et al., 2014) in ARMS and first-episode psychosis (FEP)
patients revealed more positive psychotic symptoms in women (n = 43;
total sample n = 117) and more negative symptoms in men, which, how-
ever, did not withstand correction for multiple testing. Similar small gen-
der differences were reported in three further ARMS studies-more
negative symptoms in men (men n = 159, total sample n = 239;
Rietschel et al., 2015), more unusual experiences in women (women
n = 148, total sample n = 356; Waford et al., 2015) and more depres-
sive symptoms in women (women n = 53, total sample n = 129; Pruess-
ner et al., 2017). However, these studies did not correct for multiple
testing. On the other hand, a recent study by Kotlicka-Antczak
et al. (2016) in a Polish ARMS sample did not find any gender differ-
ences in symptoms (total sample n = 99, men n = 45). The inconsistent
findings of previous studies might furthermore be due to methodologi-
cal differences between the studies, as pointed out in a previous paper
(Gonzalez-Rodriguez et al., 2014). Thus, study samples are sometimes
quite selective and not representing all men and women with emerging
illness of a defined catchment area. As some studies only had small sam-
ple sizes, their statistical power might have been too low to detect gen-
der differences, which probably are of only small or moderate effect
size. Furthermore, the instruments used to assess the risk status and the
symptomatology, correction for multiple testing and adjustment for con-
founders varied between the studies, making it difficult to directly com-
pare the findings.
To extend the existing literature regarding gender differences in
symptoms of ARMS and FEP individuals, it might be interesting to
investigate what symptoms the patients in question notice them-
selves at the onset of the change in their psychological well-being.
These individually experienced changes will subsequently be referred
to as “first self-perceived symptoms.” Although several studies have
investigated current clinical symptoms in ARMS and FEP patients,
only few have retrospectively assessed the very first self-perceived
symptoms at illness onset (i.e., when the first decline in functioning
or well-being was noted by the patient), which has been estimated to
occur on average 4-5 years before first contact with psychiatry
(Riecher-Rössler et al., 2006). Among the first was the ABC study
(Häfner, Maurer et al., 1993; Häfner, Riecher-Rössler et al., 1993),
which found that female FEP patients most frequently reported rest-
lessness, depression and worrying as their initial symptoms, while
men most frequently reported trouble with thinking and concentra-
tion and anxiety when interviewed retrospectively with the instru-
ment for the retrospective assessment of the onset of schizophrenia
(IRAOS). Iyer et al. (2008) retrospectively also assessed first self-
perceived symptoms in FEP patients (using the Circumstances of
Onset and Relapse Schedule) and found symptoms of depression and
anxiety to be the most frequent signs. However, the authors did not
report gender-specific early symptoms. An earlier publication of our
own group (Aston et al., 2012) compared first self-perceived symp-
toms independent of gender in ARMS, FEP and depressive disorder
patients and found “loss of energy” and “difficulties concentrating” to
be the most frequent first self-perceived symptoms in the ARMS group,
while FEP patients reported “depression” and “irritability” as first self-
perceived symptoms. Furthermore, there was a considerable overlap of
the first self-perceived symptoms between the three groups.
To the best of our knowledge, no study has yet investigated gen-
der differences in first self-perceived symptoms in both ARMS and
FEP patients. Such investigations could improve not only our under-
standing of the aetiopathology of psychotic disorders but also their
early detection and treatment (Riecher-Rössler & Häfner, 2000; See-
man, 2013), which has become a major goal in psychiatry during the
last 2 decades (Riecher-Rössler & McGorry, 2016).
Thus, the aim of the present study was to contribute to this field
of research by investigating whether there are gender differences in
the very first self-perceived symptoms in male and female ARMS and
FEP patients. Based on the above-described literature, we hypothe-
sized that overall only small gender differences would be observable
in the first self-perceived symptoms of ARMS and FEP patients.
2 | METHODS
2.1 | Recruitment and screening procedure
ARMS and FEP patients were recruited for this study from March
2000 to March 2016 via the FePsy (Früherkennung für Psychosen;
English: early detection of psychosis) clinic of the University of Basel
Psychiatric Hospital, Switzerland. A detailed description of the FePsy
study procedure can be found elsewhere (Haller et al., 2009; Riecher-
Rössler et al., 2007). ARMS patients were identified using the Basel
Screening Instrument for Psychosis (BSIP) (Riecher-Rössler et al.,
2008), which is based on the PACE criteria (Yung et al., 1998) with
one additional inclusion category. Inclusion as ARMS patient required
one or more of the following: (1) “attenuated” psychotic symptoms,
(2) brief limited intermittent psychotic symptoms (BLIPS), (3) a first
degree relative with a psychotic disorder plus at least two risk factors
or (4) combination of unspecific risk factors according to the BSIP
(Riecher-Rössler et al., 2008). For inclusion, FEP patients had to fulfil
the transition criteria for psychosis according to Yung et al. (1998),
which were also assessed with the BSIP.
The following exclusion criteria were applied: age below
18 years, insufficient knowledge of German, IQ < 70, previous epi-
sode of schizophrenic psychosis (treated with antipsychotics above a
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chlorpromazine equivalent of 2500 mg), psychosis clearly due to
organic reasons or substance abuse, or psychotic symptomatology
within a clearly diagnosed affective psychosis or borderline personal-
ity disorder (Riecher-Rössler et al., 2007).
All patients gave written informed consent. The Ethics Commit-
tee northwest/central Switzerland (EKNZ) approved the present
study.
2.2 | Assessment of first signs and symptoms and
duration of illness
The first signs and symptoms at illness onset as well as the duration
of illness (DUI) were assessed with the Basel Interview for Psychosis
(BIP; Riecher-Rössler et al., 2015). The BIP is a semi-structured inter-
view specifically developed to assess risk factors and indicators of
emerging psychosis as well as the temporal development of psychiat-
ric symptoms over the whole lifespan in ARMS and FEP patients. A
more detailed description of the BIP including its psychometric prop-
erties was described in a previous publication of our group (Riecher-
Rössler et al., 2015). The BIP contains the following 6 sections:
(1) social and physical development and family, (2) signs and symp-
toms, (3) vulnerability, (4) help-seeking behaviour, (5) illness insight
and (6) evaluation of the interview. In the item 2.2.2 of section 2,
patients are asked to openly name the first three symptoms they
noticed when they first experienced a drop in well-being or function-
ing. Only patients who could spontaneously recall at least one first
self-perceived change were included in the present study.
Each of the reported symptoms was subsequently categorized by
the rater to 1 of 62 pre-defined single symptoms and one of the fol-
lowing 14 symptom clusters: (1) Worries, agitation, anxiety; (2) Physi-
cal complaints; (3) Thinking, concentration; (4) Compulsions;
(5) Mood, emotions; (6) Sensitivity, suspiciousness; (7) Social isolation,
behavioural changes; (8) Supernatural, inexplicable experiences;
(9) Derealisation, depersonalization; (10) Hallucinations; (11) Delu-
sions; (12) Thought insertion, broadcasting and withdrawal; (13) Feel-
ing controlled by outside forces and (14) Problems with social
adjustment.
It should be noted that the clusters concerning hallucinations and
delusions capture sub-threshold as well as full-blown psychotic
symptoms.
DUI was determined with the BIP by assessing the date of the
first self-perceived sign or symptom and the date of first contact with
our early detection service, and by subsequently calculating the time
difference in months.
In addition, the Brief Psychiatric Rating Scale, Expanded version
(BPRS-E; Lukoff, KH, & Ventura, 1986; Ventura, Nuechterlein, Liber-
man, Green, & Shaner, 1993) and the Scale for the Assessment of
Negative Symptoms (SANS; Andreasen, 1989) were used to obtain
observer-based ratings of current symptomatology.
In the FePsy study, each patient is taken care of by a case-
manager (CM) who is either a psychologist or psychiatrist. All assess-
ments are organized by the responsible CM and all clinical interviews
are carried out by the CM. The following clinical interviews are part
of the FePsy study (in order of conduct): BSIP, structured clinical
interview for Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition (DSM-V) (SCID) and BIP. To assure a proper conduct of
the interview, all CMs get an extensive training prior to their first
assessment. Furthermore, all CMs take part in monthly psychopathol-
ogy trainings including regularly the BIP. All trainings (pre-assessment
trainings and monthly psychopathology trainings) are led by an expe-
rienced clinical psychologist or the head psychiatrist.
2.3 | Statistical analyses
The socio-demographic variables (i.e., age and years of education)
as well as clinical characteristics (i.e., DUI, BPRS positive symptoms
according to the factor analysis of Velligan et al., 2005, SANS total
score) were compared between women and men in the ARMS, FEP
and total groups using t-tests, except for the comparison of dura-
tion of untreated illness, where analyses were conducted using
non-parametric Mann-Whitney U test, due to its non-normal
properties.
The most frequently reported first self-perceived symptoms were
listed on a single-item level. Logistic regression was used to compare
the most commonly reported single items in the total sample, with
presence of symptom (1 = yes/0 = no) as dependent variable and
gender and group as independent variables.
Due to their great number, the single items were subsequently
summarized on a cluster level in order to achieve more power in the
analysis and to facilitate the interpretation of the results. Differences
regarding the self-perceived symptoms on a cluster level were also
analysed in the total group using logistic regression, with presence of
symptom cluster (1 = presence of at least 1 symptom of the cluster/
0 = otherwise) as dependent variable and gender and group as inde-
pendent variables. In case of a significant interaction between gender
and group, gender differences were analysed separately for ARMS
and FEP patients. Complete case analysis was used to deal with miss-
ing values.
All data were analysed using the R environment for statistical com-
puting (R Core Team, 2016). The level of significance was set at .05.
3 | RESULTS
3.1 | Socio-demographic and clinical characteristics
During the recruitment period, 181 ARMS and 132 FEP patients
were recruited for the FePsy study. Of these, 136 ARMS (91 men,
45 women) and 89 FEP patients (63 men, 26 women) had completed
the BIP items regarding first self-perceived symptoms and thus were
included into this study. Excluded patients were not statistically dif-
ferent from included patients with regard to socio-demographic char-
acteristics. Socio-demographic and clinical characteristics of the final
sample are presented in Table 1. FEP patients were significantly older
than ARMS patients. However, age did not differ between men and
women, and there were no gender differences in years of education
and DUI.
In the total sample, men scored significantly higher on the SANS
total score than women. However, when ARMS and FEP patients
were analysed separately, this difference was not significant.
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Women had significantly higher scores in the BPRS Positive
Symptoms Scale than men, in the total sample as well as in the ARMS
subgroup.
3.2 | Most common first self-perceived symptoms:
Single-item level
The five most frequently reported first self-perceived signs and
symptoms in male and female ARMS and FEP patients are listed in
Table 2.
Logistic regression models for each of the five most commonly
reported symptoms revealed a significant main effect of gender in
the absence of a significant group x gender interaction for the symp-
tom “Unusual anxiety, fears” (P = .016; OR = 0.361 [0.154; 0.830]),
indicating that women reported this symptom more frequently than
men, regardless of diagnostic group.
Two more effects were significant on a trend level: First, there
was an interaction effect of group x gender for the item “Unusual dif-
ficulties concentrating” (P = .062; OR = 0.219 [0.043; 1.069]), which
was due to a non-significantly higher frequency of this symptom in
male ARMS compared to female ARMS patients (P = .356) and a
trend-wise significantly higher frequency of this symptom in female
FEP compared to male FEP patients (P = .098).
Second, there was a trend-wise main effect of gender for the
item “Withdrawal, avoiding contacts” (P = .056; OR = 2.510 [1.051;
7.373]), indicating that this item tended to be more frequently
reported by men than women, regardless of diagnostic group.
3.3 | Most common first self-perceived symptoms:
Symptom cluster level
Frequencies of the 14 first self-perceived symptom clusters of the
BIP in male and female ARMS and FEP patients are shown in
Figure 1.
In the logistic regression models, we found significant main
effects of gender in the absence of significant group x gender interac-
tions for the symptom clusters “Worries, agitation, anxiety” (P = .006;
OR = 0.395 [0.201; 0.769]) and “Hallucinations” (P = .047; OR =
0.294 [0.082; 0.974]), indicating that women reported these
symptom clusters more frequently than men independent of diagnos-
tic groups. However, as mentioned earlier, the cluster “Hallucinations”
includes full-blown as well as sub-threshold symptoms.
Furthermore, there was a significant group × gender interaction
for the symptom cluster “Thinking, concentration” (P = .012; OR =
0.152 [0.034; 0.652]), which was due to a significantly higher fre-
quency of this symptom cluster in male ARMS compared to female
ARMS patients (P = .014) and a non-significantly lower frequency in
male FEP compared to female FEP patients (P = .232).
We also found a significant main effect of diagnostic group for
the symptom cluster “Delusions” (P = .039; OR = 3.764 [1.190;
18.320]) in the absence of a significant group x gender interaction,
indicating that FEP patients reported this symptom cluster more fre-
quently than ARMS patients, independent of gender.
Additionally, there was a trend-wise main effect of diagnostic
group for the symptom cluster “Mood, emotions” (P = .059; OR =
0.542 [0.281; 1.007]), which was due to a higher frequency of this
symptom cluster in ARMS than in FEP patients.
4 | DISCUSSION
In this study, investigating for the first time gender differences in
both AMRS and FEP patients in the first self-perceived signs and
symptoms at illness onset, only few gender differences were found
with women reporting more frequently anxiety and positive psychotic
symptoms (single item “Unusual anxiety, fears”; symptom clusters
“Worries, agitation, anxiety” and (sub-threshold) “Hallucinations”) and
men reporting (trend-wise) more frequently negative and cognitive
symptoms (single items “Withdrawal, avoiding contacts” and in the
ARMS group “Unusual difficulties concentrating”; symptom cluster
“Thinking, concentration” only in the ARMS group).
When comparing ARMS and FEP independent of gender, the
symptom cluster “Delusions” was more frequently reported by FEP
than by ARMS patients while the symptom clusters “Mood, emotion”
was more frequently reported by ARMS than FEP patients.
These findings are consistent, at least in part, with the only previ-
ous study that has investigated gender differences in first self-
TABLE 1 Socio-demographic and clinical characteristics
All ARMS FEP
Women Men
P value N
Women Men
P value N
Women Men
P value NN = 71 N = 154 N = 45 N = 91 N = 26 N = 63
Age 28.3 (9.59) 26.3 (6.41) 0.102 225 26.5 (9.20) 25.3 (6.06) 0.400 136 31.4 (9.62) 27.7 (6.65) 0.081 89
Years of education 11.9 (3.10) 11.3 (2.76) 0.189 225 11.5 (2.83) 11.3 (2.60) 0.624 136 12.5 (3.48) 11.4 (3.00) 0.153 89
Duration of
untreated
illness [months]a
36.0 (76.1) 33.4 (61.7) 0.986 211 38.0 (72.0) 34.0 (60.0) 0.506 128 12.0 (55.3) 29.0 (68.0) 0.402 83
SANS total score 19.3 (15.7) 25.5 (17.0) 0.010* 218 18.6 (15.5) 24.4 (17.3) 0.056 133 20.6 (16.2) 27.2 (16.7) 0.105 85
BPRS positive
symptoms
10.3 (4.34) 8.98 (4.44) 0.036* 218 7.84 (2.44) 6.42 (2.21) 0.002* 132 14.4 (3.58) 12.8 (4.20) 0.065 86
Values are given in means; standard deviation in parentheses.
ARMS = at-risk mental state; FEP = first-episode psychosis.
a Values are given in median; interquartile range in parentheses.
*Significant at P < .05.
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perceived symptoms in FEP patients (Häfner et al., 1995). This study
also found higher rates of worrying among the very first self-
perceived symptoms in women and found men to report more trou-
ble with thinking and concentration as their first self-perceived symp-
tom, which we could only find in our male ARMS patients.
The above-reported gender differences in first self-perceived
symptoms was also reflected in our measures of current symptom-
atology (i.e., SANS and BPRS), in which men scored higher in negative
symptoms and women in (sub-threshold) positive symptoms. Further-
more, these results are in line with some previous studies that have
investigated gender differences in current symptomatology separately
in ARMS (Barajas et al., 2015; Pruessner et al., 2017; Rietschel et al.,
2015; Waford et al., 2015) and FEP patients (Moukas, Gourzis, Bera-
tis, & Beratis, 2010; Thorup et al., 2007). These studies also pointed
towards more negative symptoms in men and more (sub-threshold)
positive symptoms in women in ARMS and FEP patients. However,
as already discussed earlier, other studies could not confirm these
findings and did not reveal significant gender differences in the psy-
chopathology of ARMS and FEP patients (e.g., Bertani et al., 2012,
Gonzalez-Rodriguez et al., 2014, Kotlicka-Antczak et al., 2016). In an
attempt to synthesize the above findings, it might be speculated that
small gender differences in symptoms of the emerging disease exist,
with more negative and cognitive symptoms in men and more anxiety
or affective/ (sub-threshold) positive symptoms in women. However,
the size of this effect is probably small, such that differences in the
statistical power of the studies led to heterogeneous results. It should
be noted that it is possible that more pronounced gender differences
might emerge in FEP patients as compared to the ARMS patients due
to the more unspecific nature of this latter subsample (Fusar-Poli
et al. 2012).
Still, as shown for example by Walder et al. (2013), gender could
improve the prediction of psychosis by moderating the influence of
other important predictors, such as social functioning and positive
psychotic symptoms.
There are also several limitations of our study. First, the BIP
items that we used to measure first self-perceived signs and symp-
toms did not allow differentiating between sub-threshold and full-
blown psychotic symptoms. Hence, no final conclusion can be drawn
on whether the reported gender difference in the symptom cluster
“Hallucinations” was due to sub-threshold or full-blown symptoms.
However, given that psychoses usually do not start abruptly (i.e., with
full-blown symptoms), it is likely that the hallucinations that were
reported as first symptoms were mostly of sub-threshold severity.
Second, despite the attempt to capture first self-perceived symp-
toms already in the prodromal phase, it needs to be noted that on
average there were almost five years between the appearance of first
symptoms and the time point of the interview, which may have led
to a recall bias. However, as no gender difference was found in our
sample regarding DUI, it is not likely that this has influenced the
observed gender difference. Last, the smaller number of FEP patients
in the present study might have led to a lack of power to detect pos-
sible gender differences in this group compared to the larger ARMS
sample.
In interpreting these patterns, it should also be kept in mind that
awareness of the symptoms and insight into the illness might be
impaired in patients suffering from psychosis. According to a recent
review by Gerretsen et al. (2014) insight into schizophrenia is espe-
cially impaired in first-episode patients, while it is still mostly intact in
the premorbid phase. Furthermore, men and women may differ in
their symptom awareness, their illness insight and their willingness
and ability to report specific symptoms (Berger, Addis, Reilly, Syz-
dek, & Green, 2012; Riecher-Rössler, 2010). Thus, it is possible that
the few observed differences are at least partly due to reporting bias.
In conclusion, this study revealed small gender differences in
ARMS and FEP patients, with women reporting trend-wise less fre-
quently negative and cognitive symptoms and significantly more
often anxiety and (sub-threshold) positive symptoms than men. In
clinical practice, it might be important to also think of an emerging
psychotic disorder when women present with anxiety symptoms,
TABLE 2 Most frequently reported first self-perceived signs and
symptoms
Rank Symptom Frequency Percentage
ARMS women (N = 45)
1 Depressed, not able to feel joy 13 28.9
2 Unusual anxiety, fears 12 26.7
3 Loss of energy, slow, weak 8 17.8
4 Unusual difficulties concentrating 6 13.3
5 Sleeping problems for more than
1 week
5 11.1
5 Unusually sensitive, thin-skinned 5 11.1
5 Withdrawal, avoiding contacts 5 11.1
ARMS men (N = 91)
1 Depressed, not able to feel joy 23 25.3
2 Unusual difficulties concentrating 18 19.8
3 Withdrawal, avoiding contacts 17 18.7
4 Loss of energy, slow, weak 14 15.4
5 Unusual anxiety, fears 13 14.3
FEP women (N = 26)
1 Unusual difficulties concentrating 6 23.1
2 Depressed, not able to feel joy 5 19.2
2 Unusual anxiety, fears 5 19.2
4 Heard voices when nobody was
there
4 15.4
5 More nervous, restlessness 3 11.5
5 More sorrows, not able to stop
worrying
3 11.5
5 People tried to harm, poison, chase
or kill me
3 11.5
5 Sleeping problems for more than
1 week
3 11.5
5 Unusually frequent headaches,
other physical complaints
3 11.5
5 Unusually sensitive, thin-skinned 3 11.5
FEP men (N = 63)
1 Depressed, not able to feel joy 15 23.8
2 Withdrawal, avoiding contacts 14 22.2
3 Irritable, annoyed, unusually
quarrelsome
8 12.7
4 Loss of energy, retarded, weak 7 11.1
4 Unusually suspicious 7 11.1
ARMS = at-risk mental state; FEP = first-episode psychosis.
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because on one hand, these symptoms seem to mark more often the
beginning of a psychotic disorder in women than in men, and on the
other hand, because they might be more easily misattributed to a
depressive disorder in women due to the higher prevalence of depres-
sion in women. In men, on the other hand, social withdrawal should be
taken more seriously as a potential first sign of emerging psychosis.
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